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INTRODUCTION 
          One of the most common dermatological problems is inflammatory skin 
diseases. They occur in various forms, from acute infrequent rashes in unison 
with skin itchiness and redness, to chronic forms such as psoriasis, seborrheic 
dermatitis, dermatitis (eczema), and rosacea. In these inflammatory 
diseases, psoriasis is a common, chronic, mutilating, inflammatory, and 
proliferative condition of the skin. In psoriasis both genetic and environmental 
influences have a crucial role38
             To understand the pattern of psoriasis, many studies are done recently. 
This recent progression shows that the local and systemic cytokines regulation 
contributes an important role in pathogenesis
.   
3
               Psoriasis occurs in global. It affects almost the entire age irrespective 
of women and men, in all countries, despite the consequences of racial origin
.   
78.  
In 1979 to 2008, the scrutinisation of the global trends in prevalence shows that 
existing prevalence has greater than before from 4.8% to 11.4% 78, but it is 
middling about 4.6% in developing countries as per Parisi.R et al studies21.  But 
in majority of contribute, prevalence ranges 1.5 and 5% in developed countries. 
There are more evidences to put forward that the psoriasis prevalence is in a 
rising condition 78. The prevalence of psoriasis in India is 0.44 to 2.8%. The 
point prevalence is 8%.
         
 [20] 
              Psoriasis is considered equally prevalent in both sexes78. To compare 
with males, the age of occurrence is younger in females. But there is a 
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significant difference present in the age of onset. It appears as bimodal 
distribution of the age of with two peaks in the occurrence – the first peak is 
from 16 to 22 and the second one is from 57 to 60 years of age. It also occurs in 
children76
                  In some families, psoriasis runs more frequently. 41% risk of child 
developing psoriasis if both parents are affected, if one sibling is affected it is 
6% and if one parent is affected the risk is 14% 
. 
21
                 Most common representation of the disease is reddened 
erythematous, scaly, sharply demarcated, indurated skin plaques, frequently 
with itching, stinging and irritation
. 
4,22,76. Psoriasis can occur anywhere on the 
body, but the scalp, face, palms, elbows, knees, legs, lower back, and soles of 
the feet are chiefly affected sites23. It is present in different types of 
morphological appearances such as seborrheic, geographic, exfoliative, 
eczematous, pustular, rupoid and guttate 38
               The etiology is local hyper proliferation and increased turnover of 
KCs due to climatic change, particularly the winter season and the 
angiogenesis, induced by proangiogenic cytokines VEGF, IL-8 was first 
thought to be the reason.   
.  
                Later then some other studies suggested that the pathogenesis is due 
to the vital participation of keratinocytes, natural killer cells, macrophages, T 
cellsand antigen presenting cells and natural killer cells3,58. Lastly it was 
hypothesized that it is an immune mediated disorder with cutaneous and 
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systemic over expression of a number of proinflammatory cytokines; most 
predominantly type-1 cytokines for example IL-2, IL-6, IL-8, IL-12, IFN-
gamma and TNF-alpha. After the detection of IL-23, this conclusion was 
challenged and then experimental and clinical facts put the center of attention 
on the IL-23/Th17 axis in psoriasis 5
                Now the conclusion is, for the initiation, maintenance and recurrence 
of skin lesions is attributable to over expression of these proinflammatory 
cytokines especially the IL-23/Th 17 axis. As well the keratinocytes 
hyperproliferation and the composition of inflammatory cells inside the plaques 
are also to be headed by cytokines
. 
3,4,75. 
                         As per Fotiadou et al study, IL-23, IL-17A, and IL-22 plays a crucial 
role in the activity of psoriasis and the early stages of the disease. These 
cytokines levels are when compare with the stable disease shows a significant 
increase in active disease15. IL-23 highly significantly negatively correlated 
with disease duration1.  
                 Like other noncommunicable diseases, Psoriasis affects the quality 
of life to a particular degree21. As compared with other skin inflammatory 
diseases, they have greater percentage of comorbidity for example coronary 
artery disease, arthritis, metabolic syndrome consist of diabetes mellitus, 
dyslipidemia, and hypertension,. 
                Patient may experience considerable physical discomfort and 
disability depending on the seriousness of the disease and site of skin lesions.  
78,67. 
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Itching and pain can disturb the day today life activities like, self-care and 
sleep.  Certain occupations and participating in some of the sports and mingling 
and engaging with family members and others can be prevented by these skin 
lesions. Some individuals may feel poor self esteem leads to depression and 
anxiety 16,21. Epidemiological studies also have shown that an increased 
standardized disease mortality in patients with psoriasis, particularly related to 
cancer and heart16. 
                      The diagnosis of psoriasis is usually based on the presence of typical 
skin lesions. And rarely the biopsy is needed.21 Serum IL-10 and IL-23 levels 
were notably raised in active psoriasis patients, indicates their role in disease 
pathogenesis and IL-23 negatively associated with extent of the disorder.
              Right now there is no cure for psoriasis. 
1 
 So many researches are 
underway for better treatment and possible cure. Major thing to improve lives 
of patients with psoriasis is knowledge and wakefulness about the disease and 
treatment107
                In this way, the aim of the study is to assess the IL-23 levels in early 
cases. By the IL-23 level, in future can cure or prevent the comorbidities and 
mortality in the patients or the person with a family history of psoriasis. 
. In these some works currently leads to molecular therapeutic 
aspect.  
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AIM AND OBJECTIVES 
 AIM: 
          To assess the level of IL-23 in psoriatic patients.  
OBJECTIVES:                 
• To assess the level of IL-23 in psoriatic patients and healthy individuals. 
• To compare the IL-23 level in psoriatic patients and healthy individuals  
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REVIEW OF LITERATURE 
DEFNITION: 
               Psoriasis is a chronic, common, noncontagious, 
               The degree, periodicity of flares and duration is variable in each 
patient. Frequent morphological variants are also seen.
inflammatory, 
proliferative, disfiguring condition of the skin. It is stigmatizing skin disease 
together with profound impaired quality of life, having genetic and 
environmental impact in main play. The mainly distinctive lesions consist of 
sharply demarcated, indurated, scaly, red plaques. Over the scalp and extensor 
surfaces these plaques present predominantly.  
76
HISTORY OF PSORIASIS:  
. Psoriasis is not 
spreaded by physical or sexual contact.  Lifestyle, diet, or bad hygiene is also 
not the cause for psoriasis. 
               Psoriasis was a known word only from the second century, before that 
no such term was used by the people. By 19th century there was clear 
relationship between psoriasis and articular symptoms were recognized36.The 
terms psora and lepra was used for diseases that can be recognized as psoriasis 
by Hippocrates. Later Willan named it, discoid lepra Graecorum and psora 
leprosa in thought of two distinct form of psoriasis. But these two variants were 
pointed out the one disease, i.e. psoriasis was implied by Ferdinand Von Hebra 
the Viennese Dermatologist 57. The psoriatic arthritis was first described in 
early 19th century.  
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INCIDENCE AND PREVALENCE: 
               For the incidence of psoriasis, only few studies are there. Evocative 
reliable datas are difficult to find because of there is no compulsion for 
registration of cases of psoriasis in hospitals. In 3 countries Morocco, Algeria 
and Tunisia, a 14 days psoriasis screening study was performed parallel in 
2012 to know the incidence. The projected psoriasis incidence are 
correspondingly15.04, 10.36 and 13.26 78,45
               Worldwide psoriasis is a common disease. In most of the countries 
apart from of ethnic origin, men and women of all ages are affected. The 
psoriasis prevalence from a variety of numbers of studies it is evidence for a 
discrepancy between 0.09% and 11.4% among all countries. Prevalence is 
around 1.5 and 5% in developed countries generally. There is a steady state 
increase on the prevalence of psoriasis is suggested by some studies 
.  
78. 
Population prevalence is of 1.5-3%4. The prevalence in south India was only 
2.8% 20
                  In clinical category, the frequently occur one is chronic plaque 
psoriasis (50%) . In descending order, the quotient of involved sites were the 
trunk, limbs, scalp, face, palms-soles and flexures.30% shows worsened 
clinical picture in winter season.
.  
 39
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AGE AND SEX DIFFERENCE:  
                  The onset of psoriasis stands for a constant lifelong risk. Any age 
can develop the disease64. It has a diagnostic problem as well as has 
insurmountable clinical representation even in neonates but incidence among 
neonates is rare.66 1.1: 1 is the male female ratio in the psoriasis patients. 
Highest prevalence was noted in the age group of 21-30 and 41-50 years, 
comprising 25% each.
SEASONAL INFLUENCE/CLIMATIC GOVERN: 
 39  
                 Cool temperature, dusk, and low moisture of wintry weather trigger 
the blazing of psoriasis. This type of climatic oversee can augment skin 
permeability, epidermal thickening, and arouse inflammatory mediator 
assembly8. The deterioration of severity in summer may be attributed the 
immunomodulatory and bactericidal effects of the sunlight. 
FAMILY HISTORY: 
8, 96 
                Lower numbers of family history was account by the Indian studies. 
14% of positive family history was reported by Bedi in his study. While only 
2% of family history was accounted by Kaur et al.  84% affected in First 
degree relatives while 12% of cases in second degree family relatives. In 
psoriasis family history, barely minimal studies are done, so the specific 
statistical figures on familial incidence is not available 39
 
. 
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MODE OF INHERITANCE: 
                Probability of a positive family history and earlier onset is greater 104. 
Various researchers agree that genetic basis take part as an etiologic role, for 
the prevalence of psoriasis in family’s leads to the guess that there is no 
conformity on the mode of inheritance. The elucidation of the observations 
ranges from simple dominance to digene recessivity. 
             The elemental theories of the form of inheritance of psoriasis are:  
94,83 
* Autosomal dominant with incomplete penetrance;  
* Double autosomal recessive; 
 * Multifactorial94
               Genomic imprinting proposes an epigenetic effect that is, based on the 
sex of the transmitting parent, the degree of difference in expression of gene 
occurs. A non-mendelian mode of transmission has also been proposed for 
psoriasis and PsA by genomic imprinting.
.    
              In genetics of psoriasis this is evidenced most convincingly by the 
report that, 63% concordance among identical twins versus 15% concordance 
among dizygotic twins. The risk for offspring is 14-15% if one parent is having 
psoriasis, and it is 41-75% if both parents are involved. The risk of subsequent 
children is 6-20% if neither parent has the disease but the child affected
84, 83 
 89
                  In P Rahman et al study, the sex of the parents with psoriasis has 
effect on the birth weight of the offspring. That is, with offspring of males with 
. 
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psoriasis weigh 270 g more than offspring of females with psoriasis. The same 
authors reresearched the same population in the Faroe Island and documented 
that a higher penetrance of psoriasis if the male parent was presumed gene 
carries or was affected 84
GENETICS:  
.  
               IL 23A gene codes for the IL-23p19 subunit has recently been found 
as proof for the genetic association with psoriasis.A familiar risk haplotype was 
recognized in IL-23R receptor gene, at 310 aminoacid proline, and at 381 
aminoacid arginine . In IL-23R, at 381 position if change the glutamine for 
arginine then it is establish, it would be defensive against psoriasis. IL-12Rβ1, 
IL-12Rβ2, p35 and p19sites polymorphism was not complexed with psoriasis 
vulnerability in these studies35 
                      In sibling pair analysis, it is confirm that chromosome 6p has the 
liability gene for psoriasis. They ascertained out that there is a strong linkage to 
replication loci on chromosomes 17 and 4, once the allele was of paternal 
origin, and was most considerable one in those families without psoriatic 
arthritis83
GENETIC STUDIES: 
. 
      Within the past decade, on the basis of genome-wide linkage studies, 
several putative loci for genetic susceptibility to the disease have been reported. 
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They found out one locus in the major histocompatibility-complex (MHC) 
region on chromosome 6 has been replicated in several populations91
            It is most commonly stated that HLA-Cw6, HLA-B13, HLA-Bw57 and 
HLA-DR7 are the HLA types associated with psoriasis. 50% percent of 
psoriasis cases coupled with PSORS1 gene
. 
91, 110. Homozygotes for HLA-
Cw0602 have 2.5 fold advanced risk of having psoriasis in compare with 
heterozygotes.
TABLE 1: Genetic susceptibility loci in psoriasis 
64 
Location 
66, 91,76 
Position concerned Genes 
PSORS1 6p21.3 Corneodesmosin, HCR 
PSORS2 17q25  
PSORS3 4q  
PSORS4 1q21 Epidermal differentiation complex gene cluster 
PSORS5 3q SLC12A8 
PSORS6 19p  
PSORS7 1p  
   
              Most recently it has been revealed that an extra gene locus for 
psoriasis liability was on chromosome 17q25. This locus is a runt-related 
transcription factor 1 (RUNX1) binding-site variant, encodes for a gene 
implicated in the growth and of blood cells, plus cells of the immune system.
  
91 
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GLOBAL BURDEN OF PSORIASIS: 
          In 2010, to evaluate the degree of dissuade or dearth of healthiness 
owing to diverse diseases was assessed by ‘The Global Burden of Disease 
Study’. The Disability -Adjusted Life Year (DALY) in one of the metrics 
frequently used for this assessment. The whole total of and years of life lost 
(YLLs) and years lived with disability (YLDs)   is equaled to DALY. One lost 
year of a healthy life is meant to be one DALY. . 
        DALY = YLD + YLL                1 DALY = 1 lost year of healthy life 
           In psoriasis the scrutiny of the Global Burden of Disease Study 
suggested that the burden is high-pitched. For psoriasis at 2010, the global 
average of DALY was estimated 1050660, which is twice in so far as for acute 
hepatitis C 12, 78
HISTORY OF PATIENTS: 
. 
The foremost symptom is generally pruritus and disturbed sleep is 
encountered by the majority of the patients. In unstable pustular or 
erythrodermic psoriasis, the common features are skin tightness and burning of 
the skin. In palmoplantar or flexural disease pain may be encountered in areas 
of fissure formation. In scalp psoriasis, peeling of scale from the lesion is a 
major symptom. 
           At any age first sign of psoriasis may appear and in common those with 
have a family history of psoriasis, sooner the onset disease are more likely to. 
Amongst the individuals the course of disease as well as the occurrence of 
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relapses and remissions varies to a particular extent. The degree of involvement 
of specific sites by psoriasis that may not be expressed by the patient, for 
example the ano-genital region it is essential to ask about 67
Table 2: Different morphology of psoriasis
. 
57
Different types of  morphologic features  
: 
1. Generalized  2. Serpiginous  
3. Follicular  4. Inverse 
5. Pustular  6. Geographic  
7. Annular  8. Guttate   
9. Nummular  10. Gyrate  
 
 PRESENTATION:  
The typical lesion is a well-demarcated from normal skin, sharply 
declined edges, itchy, pink to salmon-colored plaque covered by slackly 
adherent scales that is typically silvery white in color21,34,65,67. There is silvery 
or yellow white scaly lesion similar to mica 66.  Some lesions are presenting as 
annular, linear, gyrate, and serpiginous like different configurations 65. A clear 
peripheral zone encircles the plaques called, the halo ring of Woronoff
          NUMBER: Number of lesions may be several to single one. From one to 
several centimeters, the diameter differs. On the legs and sacral region it is 
commonly seen that the formation of coalescence of smaller plaques into large 
plaques. Involuting lesions often clear from the center initially, producing 
annular or arcuate shapes. 
. 
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HISTOLOGICAL APPEARANCE:  
           In early budding lesions vasodilatation, papillary edema and leukocytes 
infiltration pave the way to the epidermal changes. Following this compact 
hyperkeratosis, disappearance of granular layer and slight epidermal 
hyperplasia will be continued76
Acanthosis (augmented epidermal cell turnover leads to distinct 
thickening in epidermis) with uniform rete ridges descending extension and 
appearance of mitotic figures in keratinocytes
. 
 64,76.  
          Characteristic plaque, the majority portion of epidermis is shrunken 
particularly overlying the dermal papillae (suprapapillary plates). Inside these 
papillae, circuitous, dilated blood vessels can be seen. This assemblage of 
changes costs in unusual closeness of vessels within the dermal papillae to the 
overlying parakeratotic scale, and accounts for the typical clinical occurrence 
of multiple, minute, bleeding points when the scale is moved  up from the 
plaque(Auspitz sign)
The stratum granulosum is 
frailed or not present and widespread parakeratotic scale is visualized.  
64
           Neutrophils form small compilation within the parakeratotic stratum 
corneum which is called as munro microabscesses and inside the spongiotic 
foci of the superficial epidermis is known as spongiform pustules
.  
64
Histologically there is mixed dermal infiltrate, including CD4
. 
+ T cells, 
dentritic cells, macrophages and mast cells present along with distinct 
epidermal hyperplasia and parakeratosis 10. 
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In a plaque lesion, the bulged endothelial cells are activated with having 
intracellular Weibel-Palade bodies and prominent Golgi apparatus. Dermal 
blood vessel dilatation and widening of intracellular spaces occurs because of 
this. For easy migration of  inflammatory cells like macrophages etc into the 
skin, these lesional capillary loops express E- selection,  present inside the 
lesion having venous structural similarity, bridged fenestrations, put up it 
easier58,81
LATENT PSORIASIS: 
. 
            It is a state which appears before the manifestation of the signs of 
clinical psoriasis. During this period may be a few aberration present but there 
is absence of clinical manifestation or the extinction of some hidden defect. 
This latent stage may possibly occur at birth or later. No consideration of the 
age at which psoriasis appears, the clinical phase can come into view from the 
latent stage at any time. The changeover to clinical psoriasis from latent one 
mostly presents as stable form which waxes and wanes in severity, but 
infrequently transfer back to the latent period. These switchovers are "natural" 
in that no treatment brings them about. It is evident that the progression of 
clinical psoriasis often depends upon one of the "triggering stimuli" or whether 
it appears to develop instinctively38
 
. 
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PATHOGENESIS:  
It is seem to be multifactorial, whether symbolize the immune system or 
the principal disease of skin, or the immune system, or contributions from 
genetic and environmental factors is being discussed for some years.
ROLE OF OXIDATIVE STRESS: 
1,58,64 
           Recently some theories have been proposed the participation of 
oxidative stress in the pathogenesis of psoriasis. Oxidative stress is unevenness 
among oxidants and antioxidants in favor of the oxidants. This imbalance leads 
to interference in the redox signaling and control and/or molecular damage60. 
First it has been suggested that there is a compromised function of antioxidant 
system and increased reactive oxygen species (ROS) production 34
            As it is constantly exposed to UV and other environmental stresses, skin 
is a vulnerable target for oxidative damage and producing ROS 
. 
34. The nitric 
oxide synthase (NOS) expression is seen in keratinocytes the major 
composition of epidermis and fibroblasts in the dermis. Following the UV 
exposure these above mentioned cells liberated NO which plays a considerable 
role in immunosupression and erythema and 61. Increased NO• end products has 
important role in etiopathogenesis of psoriasis34. ROS mediated oxidative 
damage causes a notable raise in arachidonic acid, DNA modification, and 
secretion of inflammatory cytokines.  Lipid peroxidation of plasma membrane 
of psoriatic skin cells occurs due to ROS related oxidative damage. 34
  
. 
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IMMUNOPATHOLOGY57
            Most important hints of participation of immune system in 
pathogenesis: 
: 
1. The occurrence and emergence of abundant activated T cells in active 
psoriatic lesions. 
2. Immune mediated emergence of adhesion molecules on the surface psoriatic 
keratinocytes. 
3. The relative absence of TH
4. Lymphokine profiles signifying a T
2 related skin disorders, for example utricaria 
and atopic dermatitis. 
H
INFLAMMATORY MARKERS: 
1 disarray. 
The picture of psoriasis is thought that extremely increased rate of 
epidermal production, along with set off mononuclear infiltrate in the dermis 
beneath the affected epidermal layer3.Then subsequently following cells and 
cytokines have been thought to take part as vital role in the pathogenesis, that 
includes; Keratinocytes, Natural killer cells, Langerhans' cell, Antigen-
presenting cells, macrophages and T cells. The assembly of Th1 type cytokines, 
growth factors like keratinocyte growth factor (KGF) and vascular endothelial 
growth factor (VEGF) and etc 58
There is unusual expression of antigens such as heterodimers keratin 6–
keratin 16 and heat-shock proteins and also the TGF-α, along with 
hyperprolferation. The TGF-α is an autocrine mediator as well as a master 
. 
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cytokine significant to disease processing, present in psoriatic epidermis,  was 
evidenced by in vitro and in vivo researches. In adding up, there are 
intercellular adhesion molecule 1 (ICAM-1) and provoked expression of MHC 
class II antigens91,57
          Primary source for angiogenetic activity in the growing plaque is 
epidermal keratinocyte proangiogenetic cytokines like VEGF and IL-8. Blood 
vessels that are present psoriatic lesions have features like dilated and knotty, 
entering directly in the dermal papillary vicinity, beneath the epidermis. ICAM-
1 (CD54), E-selectin (CD62E), vascular-cell adhesion Molecule 1 (CD106), 
and MHC class II antigens, all are uttered by the lesional vascular cells shows 
the activation
. 
 91
           Recent progress in understanding the important role of T cells in 
pathogenesis of psoriasis is going on. Along with INF-γ and other above 
mentioned cytokines, the T helper-1 cells dominated cytokine milieu also 
accounts for the skin lesions.  
. 
           Current evidences suggest that IL-23 might be a key cytokine in 
psoriatic lesion.  INF-γ production and proliferation of memory Th1 cells are 
stimulated by IL-23. IL-23 would maintain a Th1-committed memory response 
by the constant propagation of memory T cells 6
  
. 
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Table 3: Cytokines in the pathogenesis of psoriasis 
CYTOKINES ROLE IN PSORIATIC PATHOGENESIS 
IL-1 Promotion of ICAM-1, VCAM-1and E-selectin on 
keratinocytes; Emergence of GM-CSF and KGFKGF in 
fibroblasts; Involvement in angiogenesis. 
IL-2 Provoke NK cell activity and T cell cytotoxicity. 
IL-6 In dermal infiltrate, boosts up the activation, proliferation of 
T cell. 
IL-8 Into epidermis repositions the neutrophils and T cells; T cell 
activation and proliferation: Firing up of angiogenesis. 
IL-12 Helps in type I T cell maturation pathway; Accelerates the T 
cell activation. 
IL-17 On the surface of fibroblast augments the expression of 
ICAM-1. 
IL-22 Improves keratinocyte mobility by induces MMP, S100, 
defensins synergistically with IL-17. 
IL-23 Core persuader of Th-1 cells and triggers the transcription of 
nuclear STAT-3; Guides to an increase the level of IL-17 & 
IL-22; Causes diverse infiltration and distinct acanthosis. 
TNF-α Arouses the synthesis TGF-α, IL-8, PAI-2, ICAM-1, GM-
CSF and β-defensins by keratinocytes: Accelerate the 
endothelial cells to produce VEGF. 
INF-γ APC activity acceleration. 
Endothelin- 1 Chemo-attractant to neutrophils; It is mitogenic to 
keratinocytes; It’s serum level is parallel to severity of 
psoriasis. 
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Table 4:Growth Factors 
Growth factors Role in psoriasis 
GM-CSF Speeds up the keratinocyte proliferation and triggers the 
neutrophils. Invigorates the proliferation and maturation of 
endothelial cells. 
EGF FAMILY In psoriasis augments the expression of amphiregulin and 
TGF-α. 
VEGF Causing erythema by up regulation in psoriasis. 
homogenization of remodeling and growth of vascular cells 
in psoriasis lesions. 
FGF Presents in both suprabasal and basal layers of the affected 
lesional skin. Has angiogenic and mitogenic property. 
NGF Over-expression in psoriatic lesion; 
Quickens endothelial cell and keratinocyte proliferation; 
Adherence molecule expression; A striking up-regulation 
of tyrosine kinase A, p75 neurotrophin receptor and NGF 
receptors. 
 
ROLE OF ICAM IN PSORIASIS: 
        Intercellular Adhesion Molecules (ICAMs) found in psoriatic plaques in a 
significant quantity are otherwise known as adhesion molecules. It includes 
ICAM-1, ICAM-2 which are along with VCAM-1, make availability of 
costimulatory signals obligatory for T-cell activation by assists the binding of T 
cells to antigen-presenting cells and keratinocytes. The interactions among 
cellular adhesion molecule facilitates the continuous recirculation of T 
lymphocytes among lymph nodes, tissues, and blood 18
  
. 
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LEUKOCYTE FUNCTION–ASSOCIATED ANTIGEN 1 (LFA-1):  
LFA-1was recognized in humans in 1982. Tthis is the element of the 
leukocyte β2-integrin family of adhesion molecules.  Heterodimer shares a 
common β chain (CD18) and a unique α chain (CD11a for LFA-1).Expression 
of LFA-1 is constrained to leukocytes.  
           LFA-1 is an integral molecule in T cell activation and leukocyte 
trafficking. LFA- 1 interrelates chiefly with ICAM-1, and too intermingles with 
ICAM-2, ICAM-3 as well as JCAM-1.  Memory T cells expresses LFA-1 in 
higher concentration compared to naive T cells. The b2 subunit of LFA-1 has 
been drawn in as important for signaling actions thought to be associated with 
this LFA-1-ICAM-1 engagement. Early studies recommended that great 
increase in the functional gluttony of T cell:APC interactions is by the primary 
role of LFA-113
 IL-23: 
. 
In 2000 during, searching for the members of IL-6 family, IL-23 was 
discovered by Oppmann and colleagues40,19
      This is discovered in 2000, more or less 15 years back, IL-23 has 
promptly shifted as a key player, and a probable therapeutic object in psoriasis 
than just a pro-inflammatory cytokine.
. 
5  IL-23, IL-12, IL-27 and IL-35 are 
belongs to the IL-12 family which is wholly are heterodimeric cytokines. Even 
though are having several structural similarities in the cytokines, downstream 
signaling components and receptors, they all are  
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differ in their biological activities. In the development of Th1 and Th17 cells, 
these two IL-12 and IL-23 play a role of predominant proinflammatory/ 
prostimulatory cytokines which contribute to the above respectively14.    IL-23 
is a heterodimeric cytokine, consisting of a unique IL-23p19 subunit 5,40. 
Belonging to the same family, IL-23 and IL-12 share a common p40 subunit6
Synthesis: It is mainly synthesized by activated myeloid cells, epithelial 
and endothelial cells
.    
5. In monocytes, monocyte derived dentritic cells(DCs) 
,and in mature DCs IL-23p19 in strongly expressed and mainly localized in 
papillary dermis19. In psoriasis, dentritic cells and keratinocytes mainly 
produced IL-235,41,42
IL-23, through TNF-α and IL-20R2 arbitrates epidermal hyperplasisa, 
hyperkeratosis, acanthosis and orthohyperkeratosis
.  
47
Structural relationship between IL-23 and IL-12: 
. 
IL-12 and IL-23 are unique because of the way of secretion as binary 
complexes82. IL-23 comprises unique IL-23p19 and IL-12/23p40 2 and IL-
23p19 is most closely related to the IL-12 p35 subunit5
           IL-12 and IL-23 are heterodimeric typical four-helix cytokines. They are 
secreted as a complex with a common binding protein termed p40 and a 
disulfide-linkage linking the helical cytokines p19 and p35. Because of 
together p35 and p19 have sequence homology to G-CSF and IL-6, both the 
two are belongs to the members of the glycoprotein (gp) 130-class of long-
chain cytokines. The p40 subunit structure resembles the class I cytokine 
. 
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receptors such as the non-signaling alpha receptors for IL-6 and CNTF. In 
essence, soluble α-receptor subunit which represented by IL-23 and IL-12 is 
constitutively associated with the class I cytokine receptors. 82
In compared to nonlesional skin, the psoriatic skin lesion has increased 
level of both p19 and p40 mRNA shows a clear cut indication that elevation of 
IL-23 and its involvement in pathogenesis of psoriasis 
. 
35
           Based on their common subunit use of p40, these ILs are important for 
cell-mediated antimicrobial and cytotoxic activities that is T helper (Th) 1-type 
responses by this it seems that these two cytokines would have superfluous 
roles in immune homeostasis. Later,it was hastily exposed that the functions 
are non-redundant
. 
82
The relative restricted expression of p40 subunits limits potential IL-23 
producing cells to monocytes, macrophages and dentritic cells. The receptor 
complex for IL-23/12 is expressed or up regulated on T and NK cell and 
myelomonocytic lineage including DC. The immune response of both IL-23 
and IL-12 are comparable, but distinct.IL-12 mainly stimulates the IFN-γ 
production in naïve T cells. Production of memory Th1 cells and IFN-γ 
synthesis is better
.  
 stimulated by IL-236
Functional difference between IL-23 and IL-12 in psoriasis:
. 
• IL-23 signals through IL-23R and IL-12Rβ1, while IL-12 signals through 
the IL-12Rβ1 and IL-12Rβ2 subunits. 
2,9 
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• IL-23 accelerates the JAK-STAT pathway activity but acts largely on 
STAT3 and IL-12 of JAK2 and TYK2 pathway leads to phosphorylation of 
STAT4 and other STAT molecules.  
• . IL-23 brings on IL-17A, IL-17F activity and/or IL-22, and stabilizes Th-17 
cell but IL-12 promotes the synthesis of IFN-γ, which is needed for the 
progression of Th1 immune responses 2,9
IL-23/ Th-17 AXIS:  
. 
In past years major advances in understanding of psoriasis from genetic, 
immunological and clinical findings, all unambiguously converge on the 
pivotal role of the IL-23/Th17 axis5,19
           The pathophysiology of psoriasis can be divided into two discrete 
immune-mediated phases:  
. 
 Initial Phase 
 Amplification Phases.
 Initial phase:  
11,59 
Resident dentritic cells and keratinocytes perturbation by trauma and/or 
the following stimulation of pattern recognition receptors (e.g. dectin-1, TLR-
2, and TLR-4) in a genetically prone skin lead to stimulation of the innate 
immune system. This cataclysm of macrophages, dentritic cells and diverse 
cytokines triggers the production of IL-12 and IL-2335
 
.  
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 Amplification phase:  
By the adaptive immune response, these two cytokines make the bridge 
from initiation to the amplification phase11,59. But this leads to persistence and 
proliferation of Th17 cells inside the lesion. Following this Th17 cells may 
enter into the skin, and expression of chemokine receptors, was recently 
explained 35
Th17/IL-23pathway promotes chronic inflammation
. 
11. And this pathway 
adds to the complexity of psoriasis pathogenesis and provides targets for newer 
drug development 11.  IL-23 attaches and signals by means of its heterodimeric 
complex receptor compiled of subunits IL- 23R and IL-12Rβ1. IL-23R is an 
exclusive in IL-23Rcomplex. IL-23R expresses at memory T cells, DCs, 
natural killer cells and monocytes.43,44,45
           IL-23 is implicated in propagation of memory T cells, when compare to 
naïve T cells which does not responds to IL-23 due to minimal expression or no 
subunit of IL-23R.  IL-23 is responsible for differentiation and expression of 
Th17 cell population which is exemplified by the synthesis of the IL-17A and 
related proinflammatory cytokines
. 
19,17,40,46
IL-23R is acquaintance with Jak2. Stimulation of IL-23 is directed to 
ligand induced transphosphorylation and autophosphorylation of Jak2. 
Activated Jak2 in sequence phosphorylates the tyrosine molecules situated in 
the receptor subunits intracellular domain. Activator of transcription (STAT) 
and signal transducer molecules tie up with the docking sites of phosphorylated 
. 
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tyrosine residues. After tying up, phosphorylation of these molecules occur. 
Now in IL-23 signaling pathway, these above mentioned molecules particularly 
STAT3 acts as the main participant19,43
For Th17 cell development, activation of STAT3 and involvement of the 
orphan nuclear receptor RORα, aryl hydrocarbon receptor and the 
Transforming growth factor-β1(TGF-β1)  are needed
.     
19,35. Phosphorylated 
STAT-3 particles dimerizes from two identical monomers and transfer into the 
nucleus, invoking cytokine transcription, like IL-17A, IL-17F, IL-22 and INF-
γ. Aminoacid switching, in the IL-23R subunit that is, arginine to glutamine 
and leucine to proline, confer protection against psoriasis.IL-23 thus promotes 
the IFN-γ production and type-1 immunity9
        The term “type-1immunity” relates to a environment enhanced natural 
killer (NK) activities and distorted towards cytotoxic functions of TH1, CD8+ 
T cell and. The major function of type 1 immunity is to execute intracellular 
pathogens or cancer cells. Many tissue destructive inflammations for which 
firstly TH1 cells were blamed, but in reality it is mediated by TH17 cells. 
Immunopathology, tissue damage and disease onset is due to uncontrolled 
type-1 cellular immune responses
. 
9
TH-17 CELLS DERIVATION: 
. 
T cells: 
       70- 80% of blood cells lymphocytes comprise T cells. They have a 
specialized cell receptor known as ‘T cell receptor’ (TCR). The main function 
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of TCR is recognition of antigen. It can act in response to only an antigen 
which is processed and presented by the macrophages like antigen presenting 
cells. 
TCR: (T cell receptor)
              CD4+ T cells migrate into skin causing aggravation of disease and 
presenting as a new lesions. As compared with T cells of peripheral blood or 
normal skin, CD4+ T cells on psoriatic lesional skin showed significant greater 
presentation of Vβ2, Vβ5.1 and Vβ6 T cell receptor.  The CD4+ T cells are the 
majority of T cells localized in the affected dermis, whereas those migrating 
into the epidermis are predominantly CD8 killer cells. The lesional CD8+ cells 
have constant oligoclonal expression of Vβ3 and Vβ13.1 T cell receptors. 
These T cells are activated and expressed in high levels of MHC class II 
molecules and CD25, IL-2.  
57 
         Most TCR comprise 2 chains- α and β.TCR does not have α/β and γ/delta 
chains. TCR is active only when both the chains (α and β), complex with CD3 
molecules. 
Factors promote the T cell migration into lesional plaque: 
The above mentioned receptors in the papillary and dermal endothelial 
cells receptors guide the T cell to ramble into the lesional skin. This  relocation 
into the psoriatic skin is accelerated by lipid mediators such as 12[R]-
hydroxyeicosatetraenoic acid, peptide chemoattractants such as MCP-1, MCP-
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2, MCP-3 and IL-8, MIP-1α and MIP-1β, IP10 and as yet other uncharacterized 
peptides57
T cell development: 
.  
          The majority of important events of T cell development take place in 
thymus. The progenitor T cells are originated from the bone marrow and then 
drifted to thymus via blood stream. The chief maturation events take place in 
the cortex, under the control of thymic hormones and lymphopoietic growth 
factor IL-17 which are secreted by thymic stromal cells.  
The antigen presenting cells differentiate the naïve T cells into Th1, 
Th2, Th17 or T-regulatory cells by stimulation of the T cell receptor and the 
fastidious release of cytokines 35
TH CELLS: 
.  
A novel TH subset, has been recently recognized as a distinct TH 
lineage named as THIL-17, TH17 or inflammatory TH (THi). Because of 
secretion of the following proinflammatory cytokines, such as TNF-α, IL-6, 
from IL-17A to IL-17F, IL-21 and IL-22, it is defined as Th 17 cell 35 
DEVELOPMENT AND DIFFERENTIATION: 
. 
In 2 ways: 
1) IL-23 dependent 
2) IL-23 independent 
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1) IL-23 dependent: 
On developing Th17 cells, the generation of IL-23R is by, intracellular 
signaling through STAT3, RORγT, and extracellular TGF-β. IL-23R upholds 
the sensitivity of IL-23 as the master cytokine by inducing the continued 
existence and multiplication of Th17 cells. The IL-23R receptor is a 
heterodimer made up of IL-12Rβ1, IL23R subunits1535
2) IL-23 independent: 
.  
       The switch from naive CD4 cells to Th-17 cells happens in the presence 
of IL-6 and exposure to extracellular transforming growth factor (TGFβ) as 
well as Toll-like receptor-activated monocytes 19. IL-1β and Tumor necrosis 
factor (TNF)-α, both these cytokines causes amplification of the Th-17 cell 
differentiation, which are mediated by IL-6 and TGF-β. The differentiation of 
the Th 17 cells from naive T cell precursors is also dependent on the 
intracellular transcription factors RORγ and STAT335
IL-1β was enough for production of both IL-17A and IFN-γ and to 
create the expression of RORC. In IL-17A-producing cells, a new marker in 
detected and named as CD161and was recommended as a novel marker for 
Th17 cells
. 
The Th17 differentiation was initiated by TGFβ and IL-6 and mediated 
by STAT3 via regulating the chromatin remodeling of the IL-17-IL-17-F locus, 
which is further reinforced by IL-23
19,24 
49.  
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Apart from the cytokine induced Th lineage formation, the 
differentiation is shown to be directly endorsed by the prostaglandin E2. PGE2 
synergizes with IL-1β and IL-23 to persuade the up regulation of IL-23R, and 
IL-1R to promote Th 17-associated profile of transcription factor, cytokine and 
chemokine receptor expression 50
 Transcription factors comprised in Th cell development: 
. 
• IFN-regulatory factor 4(Irf-4) 
• Signal transducer and activator of transcription 3 (STAT 3),  
• T cell-specific splice isoform of retinoic acid receptor-related orphan 
receptor (Ror) known as Ror-γt 
• Splice isoform of Ror- αd 
• Aryl hydrocarbon receptor (AhR) 
Cytokines produced by Th-17 cells: 
• IL-17A to IL-17F 
• Tumor necrosis factor (TNF)-α 
• IL-6, IL-22, and IL-26. 
IL-17:  
TH17 cells produce IL-17A, IL-17F, IL-6 and IL-22, all of which 
regulate inflammatory responses by tissue cells49
           It is undetectable in normal skin. It is a member of a newly identified 
cytokine family comprising IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-
17F. IL-17A often referred to as IL-17. Due to close proximity on 
.               
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chromosome, as well as co-ordinate expression pattern IL-17F shares a 
maximum homology with IL-17A50,35
        IL-17RA is uttered on B and T cells, epithelial cells, fibroblasts, 
monocytic cells and bone marrow stroma. IL-17RA signaling activates both the 
nuclear factor-kB, and mitogen activated protein kinase intracellular 
pathways
. 
35
IL-17 role in psoriasis: 
. 
 Proinflammatory activity induces the neutrophils, monocytes/macrophages 
T cells and epithelial cells to express proinflammatory cytokines, colony 
stimulating factors and chemokine 16
 Acts on macrophages to promote their recruitment and survival. 
.  
 Conscription and activation of neutrophils via effects on granulopoiesis. 35
 In inflamed tissue, inhibit the neutrophils apoptosis directly
. 
62
 It’s marked role in sub corneal accumulation of neutrophils and stimulates 
the production of matrix metalloproteases and aniogenic factors to cause 
tissue remodeling and angiogenesis. 
. 
 CXC chemokine induction.  
 Stimulates the mixture of immune and non-immune cells for the synthesis 
of proinflammatory cytokines and anti-microbial peptides.  
 Also enhance the IL-2 production capacity of human CD4+ T cells.  
 Enhance the proliferation of both conventional T (T) cells and Treg
 
 cells. 
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Mechanism of action of IL-17: 
In psoriasis, the mechanism of IL-17 activity in stems from its co-
operative gene regulation IL-22 and other stimuli. Together with IL-17, IL-22 
synergistically enhances expression of skin antimicrobial peptides including 
S100A7 (psoriasin), b-defensin-2(BD-2), and S100A8/9 (calprotectin)103. 
Supporting this, S100A7–9 is elevated in psoriasis, correlating with disease 
onset. Interestingly as the result of elevated antimicrobial peptide production 
psoriasis, patients are more challenging to skin infections than non psoriatic 
people. Another antimicrobial peptide, cathelicidin (LL37), is synergistically 
increased by treatment with IL-17 in combination with 1,25-dihydroxyvitamin 
D3. LL37-bound self-DNA fragments trigger TLR9 in DC, which induces a 
potent adaptive immune response, possibly one of the mechanisms by which 
self-tolerance is broken102
  COMORBIDITIES: 
. 
             Manifestations of psoriasis are not only restricted to the skin. In 
moderate to severe psoriasis, several other multiple comorbidities also 
complicate the other systems. Ischemic heart disease, stroke, hypertension, 
dyslipidemia, obesity/metabolic syndrome, diabetes mellitus, autoimmune 
diseases, sleep apnea and crohn’s disease are some diseases arise in psoriatic 
people21,79
  
. 
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Table 5: The symptoms most often stated by the psoriasis patient 86
Symptoms 
: 
Descending order of frequency 
Skin scaling 92% 
Itching 72% 
Erythema 69% 
Fatigue 27% 
Swelling 23% 
Bleeding 20% 
Burning 20% 
 
ASSOCIATIONS OF PSORIASIS: 
Psoriatic arthritis, immunobullous disorder, vitiligo, metabolic syndrome, 
acne, pustulosis, synovitis and hyperostosis are some clinical entities associated 
with psoriasis51
1. Psoriatic Arthritis:  
. 
Arthritis is the most common association with psoriasis was established 
out by Jean Louis Alibert in 1818. The incidence of arthritis in psoriatic 
patients is from 1.3% to34.7%. On sex predilection of PsA, there is no proper 
reliable data. Psoriatic arthritis (PsA) falls under the type of seronegative 
spondyloarthropathies.  
Diagnosis is made with signs of an inflammatory arthritis, presence of 
skin psoriasis and absence of serological tests for rheumatoid factor51,52. Based 
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on the national psoriasis foundation, up to 30% of the patients have psoriatic 
arthritis65. Usually within 10 years of the onset of psoriasis the PSA affects the 
joints and occurring PSA after 10 years of onset is low53. 27.5% of psoriatic 
arthritis patients have family history of psoriasis54
               5 types of psoriatic arthritis;  
. 
 Symmetric,  
 Asymmetric,  
 Distal Interphalangeal Predominant (DIP), 
 Spondylitis And  
 Arthritis Mutilans. 
Symmetric arthritis looks a lot like rheumatoid arthritis, but more often 
than not is milder. Asymmetric arthritis be capable of involve several joints 
with the presentation as sausage digits.DIP is classic form, but arises only in 
relation to 5% of the patients with PSA. Arthritis mutilans is dangerous and 
deforming.  The small joints of hands and feet are affected primarily by this 
type. Less than 5% of PsA will suffer by this form65
2. Obesity/Metabolic syndrome:  
. 
The other different names are insulin resistance syndrome and syndrome 
X. This syndrome includes metabolic abnormalities with high risk of coronary 
artery diseases and diabetes mellitus. The primary pathophysiology linking the 
metabolic syndrome and psoriasis engages overlie of genetic propensity and 
inflammatory pathway. Cytokines, for example IL-6 and tumor necrosis factor-
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α dysregulation leads to chronic inflammation interceded by Th-1 and Th-17 
cells. . These Th-1 and Th-17 cellsand the cytokines released by these cells 
persuades epidermal hyperplasia in psoriasis, and alienates signaling function 
of insulin, intervene the resistance of insulin resistance and change the 
expression of adipokine, and obesity. Susceptibility to psoriasis or seriousness 
of disease is due to long term inflammation and angiogenesis and these are 
promoted by hyperinsulinemia in metabolic syndrome. And moreover, the 
subsistence of genetic loci, e.g., PSORS2-4, CDKAL1 and ApoE4 and, is too 
been drawn into the joint of genetic vulnerability of metabolic syndrome and 
psoriasis. The alliance relating metabolic syndrome and psoriasis is due to the 
above mentioned shared measures 48
           Different types of surveys has accounted that increased levels of serum 
immunological markers, like IL-6, IL-2, ICAM-1 and TNF-α , in order to prove 
that it is a systemic immunological disorder. Inflammation is mainly controlled 
by hormones and cytokines derived from adipose tissue and liver by IL-1, IL-6 
and TNF-α. Common cytokine pathways are responsible for both psoriasis and 
obesity but it is yet to be answered which pathology comes first when 
psoriasis-associated obesity and metabolic syndrome is considered 
.  
79
               There are so many evidences that prove the relationship between 
psoriasis and a number of lifestyle factors for example alcohol intake and 
smoking and other diseases with psoriasis
. 
51
  
. 
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3. Cardiovascular diseases:  
            Gelfand et al used the General Practice Research Database (GPRD) to 
decide the psoriasis is an independent risk factor for myocardial infarction. 
CAD risk factors prevalence is greater in psoriatic patients. The psoriatic 
patients with raised TNF-α level has the risk of increased frequency of CAD, 
pulmonary emboli and cerebrovascular diseases occur 79. When put side by 
side to healthy population psoriatic patients had a 1.6 fold increased risk for 
venous occlusion, 2.6 fold increased risk for other occlusive vascular diseases. 
Arteriothrombotic markers like fibrinogen and plasminogen activator 
inhibitor-1 (PAI-1) levels are also seem to be increased in psoriasis79. 
                
4. Bullous pemphigoid and vitiligo:  
Along with a systemic inflammation, antipsoriatic prescriptions are 
believed (acitretin, cyclosporine) for the adverse CAD risk factors like 
elevation of blood pressure, elevation of serum levels of lipids are other 
possible optional mechanisms for CAD comorbidity of psoriasis . 
           Co localization of vitiligo and psoriasis may be possible because of 
structural abnormalities between anti stratum corneum antibodies and anti 
melanocyte antibodies. In addition, a common neuropeptide might be also 
accountable for co-habitation of psoriasis and vitiligo51
5. Psychiatric co morbidity:  
. 
Psoriasis causes important adverse effects on the psychological and 
social aspects of life chiefly due to its visibility. Daily activities, employment 
 37 
and treatment for disease were most affected physical and psychosocial factors. 
Sufferers mostly tends to avoid the social contacts because of disturbed feel, 
low self conscious, live in a constant fear of relapse or bothered by the peeling 
of the skin. 
Patients with psoriasis describe feeling of annoying or defenselessness. 
They reveal a higher rate of suicidal ideations Compare with other patients, 
thinking of suicide attempts is in a greater proportion. Among 127 psoriatic 
patients a study was conducted where about active suicidal thought was 
reported in 5.5% and “want to die” was 9.7% during the study period78
ASSOCIATION WITH PREGNANCY: 
. 
Many reports have recommended that physiological changes during 
pregnancy habitually lessening of systemic and cutaneous inflammatory 
diseases88, 89
               In pregnancy, there is a improvement in psoriasis due to hormone 
mediated down regulation of the immune system. The greatest role in the 
improvement of psoriasis is played by progesterone. The metabolizing capacity 
of keratinocyte cells on steroid hormones like estrogen and progesterone also 
believed to be altered by the hormonal changes of pregnancy. High levels of 
IL-10 in pregnancy have a favorable effect on psoriasis. In addition, some 
theories include roles of human chorionic gonadotrophin and human placental 
lactogen or the possible fetal suppression of the maternal immune system has 
too some effect on psoriasis
.  
89.   
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Up-regulation of proinflammatory Th-1 cytokines also plays a key role 
in the inflammatory streams of psoriasis. It is likely that, anti-inflammatory and 
antagonizing effects of Th-2 cytokine-mediated down-regulation on the Th-1 
cytokines improves psoriasis during pregnancy88
ASSOCIATION OF PSORIASIS AND AUTOIMMUNE DISEASES: 
. 
           We reviewed studies published in the MEDLINE database from January 
1, 1980, to June 1, 2011, and recapitulated the associations between psoriasis 
and several key autoimmune diseases, including celiac disease (CD), 
inflammatory bowel disease (IBD), multiple sclerosis (MS), systemic lupus 
erythematosus (SLE), and autoimmune thyroid disease. This review shows that 
the association among psoriasis and CD and IBD appears to be well 
described98
ANEMIA IN PSORIASIS: 
. 
                 Psoriasis is known to be one of the skin diseases which can cause 
folate deficiency. Touraine et al101 reported reduced serum and red blood cell 
folate levels in 22 out of 50 patients with psoriasis. Similar observations have 
also been reported by Shuster and Marks and Fry et al. They attributed the 
folate deficiency mainly to the increased utilization of folate by the rapid 
turnover of epidermal cells in psoriasis. The malabsorption of folate first 
proposed to occur in psoriasis by Shuster and Marks has since been noted only 
in rare cases by Touraine et al. Folate deficiency due to excessive loss in 
exfoliated skin was suggested by Hild, but was ruled out by Fry et al. In 
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contrast to the reduced folate levels, serum vitamin B12 levels are reported to 
be normal in most psoriasis patients and no evidence of impaired vitamin B12 
absorption has been detected despite abnormal Schilling test results in some 
cases. In addition, there is no increased incidence of pernicious anemia in 
psoriasis patients to our knowledge. These findings suggest that vitamin B12 
deficiency is unlikely to be a contributory factor in the megaloblastic anemia in 
psoriasis99
C-REACTIVE PROTEIN:  
.  
            In 1939, Tillet and Francis described material in the sera of acutely ill 
patients. It was attached to the cell wall C-Polysaccharide of Streptococcus 
pneumonia and agglutinated the organisms. In 1941 that material was revealed 
to be a protein and called as C - reactive protein.  
Evolution of CRP and pentraxin:  
              It belongs to pentraxin family of calcium dependent ligand binding 
plasma protein. The pentraxin family, is vastly conserved in evolution. It is   
called for due to its electron microscopic appearance and from the Greek  
penta(five) ragos(berries) with homologous proteins throughout the vertebrates 
and even in phylogenetically distant arachnid, limulus polyphemus, a 
horseshoe crab71
          In spite of the evolutionary preservation of sequence,  protein fold and 
subunit organization there are notable deviation between CRPs of different  
species. 
. 
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The disparities are based on with regard to  
• Presence and character of glycosylation,  
• capability to precipitate and aggregate ligands  
• Fine ligand-binding specificity,  
• Protomer assembly 
•  Behavior as acute-phase proteins 
• Base line circulating concentrations 
• Capacity to activate autologous complement.  
Indeed, only human CRP has been meticulously known to activate 
complement in isologues serum. These differences dominate in extrapolating 
from animal models to humans71
Synthesis:  
. 
            In the hepatocytes it is synthesized, nearly exclusively a large amount 
under the control of cytokines. But extra hepatic sites of CRP production have 
also been reported 69
         IL-1, IL-6 and TNF-α mostly controls the synthesis of CRP. These 
cytokines has power to alter the CRP levels as well and increase of CRP in 
blood and body fluids by a steady release of these proinflammatory cytokines
. 
79
Biochemistry of CRP:  
. 
          CRP is made up of five identical, non glycosylated polypeptide subunits 
each MW of 23,028 Dalton. All are non covalently attached to form a annular 
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or disk configuration by way of radial symmetry. The total mass of CRP is ~ 
115kDa. Every subunit having 206 aminoacids. 
           The family name pentraxin for CRP has come because of its pentameric 
structure. Other related proteins to CRP, belongs to pentraxin family are 
proteins such as serum amyloid-P and pentraxin-3. 
               CRP has circulating half life of 18-20 hours70,71. Each protomer has 
the characteristic “lectin fold”, composed of 2 layered β-sheets with flattened 
jellyroll topology. The ligand-binding site, composed of loops with two 
calcium ions bound 4 Å apart by protein-side chains, is located on the concave 
face. The other face carries a single α helix71
Function of CRP:  
.  
 Against break down products of cells and infectious organisms it has 
non specific host defense. 
 Stimulate the classical complement pathway by starts at C1q, resulting 
in paghocytosis via C3b receptors. 
 Has positive feedback via alternative pathway by  make a complex with 
factor H, a complementary inhibitory factor and to a great extent reduces 
the activation of late components(C5- C9).  
No genetic abnormalities have been reported for circulating CRP. It is 
catabolized when complexes are engulfed by phagocytes. 
Reference interval of CRP:  
                 In adults  < 5 mg/L. 
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Clinical significance of CRP: 
        The synthesis rate is the only determinant of circulating levels of CRP 
because the plasma half-life of CRP is stable in all conditions of health and 
disease.  Thus the rate of synthesis is directly proportional to the intensity of 
pathological process inducing the CRP production
  
72
         It is one among the strongest acute phase reactants
. 
 69
            Moreover, CRP may serve interchangeably with Psoriasis Area and 
Severity Index (PASI) as a measure of disease severity in the case of untreated 
psoriatic patients who do not have disease related arthritis
. The plasma levels 
can rise up to 1000 fold after stress, trauma, myocardial infarction, infection or 
neoplastic proliferation.  In the infection and inflammatory conditions it may 
go up to more than 5 to 10 mg/L. Only in moderate and severe forms of disease 
might have the high CRP level inferred from the literature and there is no 
enough data signifying a similar connection for mild disease.  
56
Role of CRP in psoriasis: 
. 
It is recognized as the most sensitive indicator of inflammation, even 
though it is a nonspecific cytokine. Depends amount of tissue injury and 
inflammation severity, the magnitude of CRP level will be increased.72
When compare the Psoriatic patients with severity of the disease the 
severe forms (PASI > 10) had appreciably elevated levels of CRP than with 
mild disease (PASI < 10) (44% vs 25%) (
. 
P value = 0.003). Thus, these results 
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show the characterization of CRP level in psoriasis. That is as an inflammatory 
response that worsens with increasing disease severity. Several other studies 
have also reported a correlation between PASI and increased levels of CRP. 
Thus, CRP can be considered as a useful marker of disease severity. And can 
be used to observe the disease course and severity and can able to decide the 
treatment68
CRP estimation is widely available, inexpensive, and can be simply 
carried out in an outpatient clinical setting. To evaluate psoriasis disease 
severity, CRP along with PASI can be used as a powerful and sensitive marker, 
when it is difficult to evaluate, based on visual evaluation of the lesions. It can 
be used for screening of the disease course and treatment. Elevation of CRP 
may be thought as a risk factor for CVD in psoriatic patients because there is 
some research supporting the association between inflammation and CVD in 
psoriatic cases
. 
68
CLASSIFICATION OF PSORIASIS: 
.  
I. Depends on natural history or morphology. (clinical appearance) 
II. Depends on the precipitants or age. 
III. Depends on the involved specific sites. 
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I. Depends on natural history or morphology: (clinical appearance) 
a. Plaque psoriasis (psoriasis vulgaris) 
b. Acute guttate psoriasis 
c. Unstable  
d. Erythrodermic  
e. Pustular  
f. Inverse  
II. Depends on the environmental factors: 
a. Photo aggravated  
b. Drug induced or exacerbated 
c. HIV-induced or exacerbated 
d. Alcohol misuse 
e. Cigarette smoking. 
f. Trauma  
g. Metabolic factors 
III. Depends on the involved specific sites: 
a. Scalp  
b. Flexural (inverse) 
c. Genital  
d. Nonpustular palmoplantar 
e. Nail  
f. Mucosal 
g. Ocular  
h. Facial  
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I. Depends on natural history or morphology: (clinical appearance) 
a. Plaque psoriasis: (psoriasis vulgaris) 
This is the most common type of psoriasis. In this type, there is a stable; 
red (salmon pink) scaly lesion with gradual broadening of plaques lesions 
persists for months to years. They expand very steadily and progress as 
indolent course and rarely occurs abruptly. The scaling extension may differ 
and orange-brown or waxy yellow. The most commonly involved areas are the 
elbows, knees, gluteal cleft and the scalp. There is a symmetrical involvement 
in the affected areas65. 
b. Guttate psoriasis: (eruptive psoriasis) 
 The clear marginal zone, called the halo ring of 
Woronoff may enclose the lesion. 
Most frequent in children and young adults. It arises in persons with no 
psoriasis or in people with chronic plaque psoriasis. Patients present with 
shower of tiny 2 to 3 mm erythematous, scaling papules, mostly follow the 
upper respiratory tract infection due to β-hemolytic streptococci. Pityriasis 
rosea and secondary syphilis are the differential diagnosis for the guttate 
type65,76. Mainly affected sites are the trunk, face, and proximal portions of 
limbs. Guttate psoriasis also detected after withdrawal of corticosteroid therapy 
and sunburn. Prognosis is best for children with limited disease
  
 66. 
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c. Unstable psoriasis: 
        This term usually explain the stages of disease, which is highly active and 
with unpredictable outcome76. Patients have frequent complaints of more 
itchiness, irritation and even pain. They are more intense inflammation with 
angry looking lesions. These seem to be ill demarcated, mild scaling and more 
red in color with intermittent exudation and crust. Further spontaneous 
conversion to pustular or erythrodermic psoriasis can happen. Inappropriate use 
of corticosteroids, excessive irritation, sunburn are some of the reasons usually 
associated with unstable psoriasis
d. Erythrodermic psoriasis: 
25,57 
             When affects around 90% of the body surface as a generalized form, it 
is described as erythrodermic psoriasis. Although the affected patient is having 
all the symptoms of the disease, but the generalized erythema is the most 
outstanding feature with less scaling. The face is rarely involved. It may 
present as different stages as sudden appearance of generalized erythema or 
gradual evolving from chronic plaque psoriasis. Triggering causes are 
occasionally identified25,57
e. Pustular psoriasis:  
. 
                Numerous tiny pustules develop an erythematous skin with pustular 
plaques and inconsistent scale. This type of psoriasis is either mild and 
localized in soles and palms, or extensive and life threatening [64]. Localized 
mild form is easily baffled with eczema. But generalized form, coupled with 
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fever for a number of days, , diffuse cutaneous and mucosal pustules with a 
background of severe erythema, leukocytosis, arthralgia, secondary infection 
and electrolyte disturbances64,65 episodes of fever and pustules are 
recurrent.[65] 
f. Inverse psoriasis:  
A severe, acute form (the von Zumbusch variant) can cause life-
threatening complications. 
              Affect the intertriginous areas including the axilla, groin, 
submammary region and naval. It also affects scalp, palms and soles. The 
individual lesions are finely demarcated plaques, with absence of scales 
because of their presenting areas and they may be moist65
II. Depends on the environmental factors: 
. 
a. Photoaggravated: 
           Usually the sunlight is favorable, but in little insignificant number of 
patients, psoriasis is aggravated by strong sunlight and it is the reason for 
summer exacerbations in exposed skin. Recent work has indicated that severely 
photosensitive psoriasis is predominantly female, strongly associated with 
onset age, HLA-Cw6 and family history, and different from polymorphic light 
eruption (PLE). Photochemotherapy (PUVA) may be useful in these patients.
b. Drug induced or exacerbated: 
76 
             In current clinical practice, the generally common drugs which may be 
worsen the psoriasis are Beta-adrenergic blocking agents, Lithium salts, Non-
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steroidal anti-inflammatory agents, Synthetic antimalarials, Angiotensin 
converting enzyme inhibitors, and withdrawal of Corticosteroids76,67
            Action of some medications is partially described. Such as, lithium salts 
raise proinflammatory cytokines, and rousing the cutaneous leukocyte 
recruitment; beta-adrenergic blockers may provoke epidermal 
hyperproliferation along with a decline of intraepidermal cyclic AMP; and 
chloroquine impedes epidermal transglutaminase, an enzyme that is crucially 
involved in the terminal differentiation of keratinocytes
. 
91
          Both tachyphylaxis and rebound phenomenon can occur, even though the 
psoriasis may be retort to oral corticosteroids. Withdrawal of corticosteroids 
may lead to development of unstable psoriasis or rebound the disease and, so 
the withdrawal should be secured by stable dose reduction rather than sudden 
termination
. 
67
c. HIV and psoriasis: 
. 
           HIV infection is one of the important triggering factors. [67].The initial 
clinical manifestation may be psoriasiform dermatitis. There are two different 
clinical patterns either guttate pattern with large plaques or diffuse psoriasiform 
dermatitis 91
            AIDS sometimes may aggravate psoriasis, in which the helper T cell is 
he major target. The proof is the improvement of psoriasis with the treatment of 
cyclosporine, which hampers the helper T cell function, creates a paradox that 
remains to be fully explained
. 
76. 
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d. Alcohol misuse: 
Excessive alcohol consumption is associated with moderate to severe 
psoriasis 67. Alcohol may not seem to be to induce psoriasis but worsens the 
preexisting disease. This effect seems greater in men when compare with 
women. Heavy drinkers tend to have more extensive and inflamed disease. 
Abstinence has been turned up to encourage remission
e. Cigarette smoking:  
 76,77. 
There is a predominantly a well-built association between palmoplantar 
psoriasis and cigarette smoking. Smokers are at greater risk of getting psoriasis, 
and more prone to suffer with severe disease and having psoriatic arthritis76
               Smoking provokes morphologic and functional alterations in 
polymorphonuclear leukocytes, which causes an overstated discharge of 
chemotactic factors. In some studies have shown that cigarette smoking causes 
an overproduction of transforming growth factor β, tumor necrosis factor α and 
interleukin 1β, which have been coupled with psoriasis severity
. 
92
f. Trauma: 
. 
         A vast array of local injurious stimuli has been recognized to sketch 
psoriatic lesions, includes chemical, physical, infective and inflammatory and 
surgical insults76
Psoriasis in which, the different types of trauma may elicit the disease in 
previously uninvolved skin, is called Koebner phenomena. The reported 
. 
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incidence of Koebner reaction has a wide-ranging between 38- 76%  and it 
occurs  usually after 7-14 of injury76,57,64
g. Metabolic factors: 
. 
              The early onset of psoriasis in women, with the peak around puberty, 
changes around pregnancy and provocation of psoriasis by high dose estrogen 
therapy would-be indicate a role for hormonal influence in disease76
III.  Depends on involved specific sites:  
. 
In Psoriasis the skin of elbows, knees, scalp, lumbosacral region, 
intergluteal cleft and glans penis are the regions affected habitually64
a. Scalp: 
. 
One of the commonest regions to be first affected in psoriasis is scalp. 
And it is the chiefly affected area in plaque psoriasis. Plaques have a tendency 
to be limited to hair-bearing areas, mainly at the occiput.  Extends a short 
distance away from the hairline around the ears. The hair growth rate is normal. 
Sometimes severe hair loss is associated with psoriatic erythroderma. A 
morphological entity includes the plaques firmly adherent to the scalp and 
related hair, asbestos-like scaling, has been termed as pityriasis amiantacea. It 
is most common in young children and adult. 
b. Flexural psoriasis: (Inverse psoriasis) 
Affecting the inguinal creases, axillae, submammary folds, gluteal cleft, 
umbilicus, and other body folds. More common in older adults and obesity. 
Often seen with plaque psoriasis. May occur as primary disorder or Koebner 
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phenomenon on top of infective or seborrheic intertriginous dermatoses. 
Sometimes it arouses suspicion of failure to react to antibacterial and 
antifungaldrugs.  
Fissuring at the depth of the crease and a glassy hue on the lesional 
surface is commonly seen. Usually well-defined edges seen around the lesion, 
except secondary infection or medicament dermatitis. 
c. Genital psoriasis: 
Can be considered as a type of flexural skin and there are similarities 
between psoriasis as it affects flexural and genital sites. The occurrence of 
genital involvement is to be low, but this area is not much mixed up along with 
other areas. 
d. Palms and Soles: 
Present as a characteristically scaly areas with a fine silvery scale over 
the lesion. It can be stimulated by scratching. Psoriasis keeps hold of its typical 
character, elsewhere on the hands and feet. There may be association between 
lesions and occupational irritants or trauma. 
e. Nail:  
           Common in psoriasis patients with concurrent PSa, incidence around 
70% patients. All types of psoriasis of the skin associated with nail 
involvement mostly. There is no sex predilection. When compare with those 
under the age of 20 years, patient over 40 years of age are affected twice76. 
 52 
The most common findings are observed are pitting, dimpling, 
subungual hyperkeratosis, yellow brown(often likened to an oil slick) 
discoloration, ridging and thickening & crumbling of nail plate separation of 
the nail plate from underlying bed(onycholysis)54,55,64
f. Mucosal lesions: 
. 
True mucosal involvement appears to be rare. But the plaque, 
erythrodermic and pustular forms associated with mucosal involvement. 
Geographic tongue and association of psoriasis with HLA-Cw6 provides 
further evidence that the two disorders are related. 
g. Ocular lesions: 
Ocular involvement is either directly, or by associated immunological 
phenomena. The most frequent ocular complications of psoriasis involvement 
of the eyelids or eyelid margins can leads to blepharitis. Xerosis and chronic 
non specific conjunctivitis is also seen in psoriasis. Keratitis is rare. Uveitis is 
observed with extensive psoriasis and an immunologically interceded 
complication.  
h. Facial psoriasis: 
It is the marker of severe psoriasis. Involvement of face occurs in 
patients with long duration of the disease or early onset or with nail or joint 
involvement often involved with face. More extensive treatments is needed for 
this patients. Positive family history, more severe pruritus, , and history of 
Koebner response are associated with facial involvement95. 
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IMPROVING THE QUALITY OF CARE: 
Physician Global Assessment:  
In psoriasis, the PGA scoring system is build on response to treatment as 
measured by lesion erythema, induration, and scale, with score assignments 
that range from clear, almost clear, mild, moderate, to severe. The PGA system 
demonstrates has both substantial correlation and reliability, when compared 
with the other widely used assessment tool like the Psoriasis Area and Severity 
Index. PGA scale that has undergone psychometric validation and found to 
have internal consistency, strong test-retest reliability, and validity on top of 
significant longitudinal correlation to the Patient Global Assessment (PtGA)97
Table 6: PGA grading scale: (contain a 5-point range from clear to 
severe)
. 
SCORE 
97 
DEFINITIONS DESCRIPTION 
0 Clear  No signs of psoriasis. But postinflammatory 
discoloration may be present. 
            1 Almost clear Only minimal plaque elevation, scaling and 
erythema 
2 Mild  Easy recognizable. Less than half of the face 
involved. 
3 Moderate  Moderate plaque elevation. Scaling and erythema. 
4 Severe  Very marked plaque elevation. Scaling and 
erythema 
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PRINCIPLES IN MANAGEMENT OF PSORIASIS78
           Concentration of the care of psoriatic patients involves superfluous 
treatment for the skin lesions and arthritis. Difficulty in psoriasis is, only 
recommend the drugs alone not sufficient in manage the disease but the 
required care is an unexpurgated complete individual approach of health care.  
: 
            Psoriasis management takes account of uncover the related 
comorbidities like cardiovascular disorders, hypertension and diabetes mellitus, 
dyslipidemia. More over psoriasis patients have more chances to undergo 
depression and nervousness and strong idea of suicide.  
   At standard interval the screening for the following, 
• The other related disorders 
• Drug-triggered psoriasis  
• To avoid drug-drug interactions prescribe co-medication  
• Recognition of trigger factors and their treatment 
Understanding triggers: 
    So many causative factors are documented as a reason for early 
symptoms of psoriasis to flare up of stable long term psoriasis. Realizing and 
lessening of these stimulating factors is an essential component to deal with 
psoriasis.  
 Based on different researches from various countries, obesity is identified 
as a noteworthy trigger for psoriasis.  These patients show improvement in 
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skin lesions with undergoing bariatric surgery with subsequent significant 
weight loss. Obesity is also related with reduced efficacy of psoriasis 
treatment and itself is an self-sufficient risk factor for cardiovascular 
disease. Thus, can add the weight loss intervention programs as a part of 
psoriasis management.          
 Tobacco smoking is one of the most important risk factor. Counseling of 
cessation of smoking cessation ought to be engaged in care giving.  
 Some infections are being capable of act as cause for psoriasis, for example 
streptococcal throat infection is one of the main exaggerating factors. 
Recurrent tonsillitis in grown persons with psoriasis, tonsillectomy can 
lessen the symptoms of psoriasis and minimize the requirement for 
treatment. Periodontitis has also known to be a risk factor of psoriasis.   
 Apart from of the stressor’s nature, stress is a significant a strong 
aggravating factor in all age groups.  
TREATING THE SKIN MANIFESTATIONS: 
Three main types of therapy57,78
A.  topical therapy 
: 
B. Phototherapy 
C. Systemic therapy  
1. Mild psoriasis:  
Topical therapy is usually used to treat mild cases, but reaction to 
therapy in not satisfied, proceeds phototherapy. PUVA is used to treat and its 
efficacy is extensively documented and confirmed by various studies. 
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2. Moderate to severe psoriasis: 
Require systemic therapy. Methotrexate, cyclosporin,  acitretin and      
Etretinate are usually used as first-line medications. Biologic agents and 
fumaric acid esters are can be offered as a systemic therapy. Other than 
retinoids, all therapies for psoriasis are primarily anti-inflammatory to slow 
down keratinocyte proliferation and suppress the severity of plaques.    
In the therapeutic armamentarium for patients with moderate-to-severe 
psoriasis and psoriatic arthritis, the biologic agents are the better option. 
Patients must be scrupulously monitored to assess the patients whether they can 
tolerate the biologic therapy because of potential side effects. This screen 
should include close attention to the patient's past medical history as well as 
baseline laboratory testing.
Table 7: Psoriasis treatment options on the WHO model list of essential 
medicine: 
87 
a) Anti-pruritic and anti-inflammatory medicine: 
Hydrocortisone Cream or ointment 1% (as valerate) 
Betamethasone Cream or ointment 0.1% (acetate) 
 
b) Drugs lessen skin proliferation and demarcation: 
 
 Salicylic acid Solution 5% 
 Urea Ointment or cream 5% or 10% 
Coal tar Solution 5% 
Flurouracil Ointment 5% 
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c) Systemic therapy: 
 
Cyclsporine Capsule 25mg (for 
immunosuppression)  
Methotrexate Tablet 2.5mg (as sodium salt) (for 
joint disease)  
 
             As per Sofen H et al study in 2014, in  their double blind, randomized, 
placebo-controlled study of the tolerability, safety, and clinical effect of an 
anti-IL-23-specific mAb, guselkumab was assessed in patients with moderate-
to-severe plaque psoriasis. The clinical response of the moderate-to-severe 
psoriasis to IL-23 inhibition with a single dose of guselkumab results, 
suggesting that neutralization of IL-23 alone is a promising therapy for 
psoriasis106
BARRIERS IN QUALITY CARE:
. 
• Inadequate awareness of health professionals 
 78 
          Lack of awareness of psoriasis is mostly due to inadequate instruction to 
general physicians and other health-care contributors. Contact with specialists 
at the needed situation is to make certain favorable treatment and avoidance of 
associated disorders. 
• Limited access to health care: 
           Fundamental problem met by patients. The deficit in adequate access to 
health professionals and insufficient number of professionals contributes low 
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public awareness of psoriasis and without diagnosis, without treatment, 
uninhibited progression in disease severity and disability  
• Lack of guidelines and tools for treatment 
             Have consequences like uncontrolled disease and redundant suffering, 
irrevocable joint deformities and disability. Individual comprehensive 
personalized care also often deprived. If health-care providers are conscious of 
guidelines and put into practice daily, the quality of care for psoriasis patients 
is increased. 
• Availability and cost of necessary drugs: 
Financing for treatment is disastrous to the patients and their family 
financial state of psoriatic patients. And also it is difficult to commence their 
work due to health conditions or because of bias.  
• Discrimination  
            Discrimination in opposition to psoriatic patients is directly affecting the 
ability to proper health care access. A public misconception like it is a 
communicable disorder and ends up in omit the patients from the community 
and in day to day life by surrounding people leads to lack of self confidence 
and even promote the suicidal tendency among psoriatic patients. 
• Difficulties with adherence 
            Patient adherence has inverse relationship with discontent in treatment 
and psychiatric morbidity. Reduced adherence is problem related to topical as 
well as systemic therapy which includes biologic agents, but highest with 
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topical therapy. It is to some extent due to lack in the communication regarding 
misperception of possible adverse events, directions on how to use the drug, 
and erroneous prospect about the speed and degree of deterioration of 
symptoms and signs. 
KEY ACTIONS TO STRENGTHEN SERVICES: 
• Developing better way to access the services and necessary medicines to 
control psoriasis. 
• Organization of helpful procedures or steps that foster the development 
of organizations, offered support for psoriatic patients and their families. 
• Ensuring the commitment of policy-makers and provision of adequate 
managerial support; 
• Education and training for health care providers, particularly in primary 
care settings. 
• Formation of an interior system among dermatologists and required 
pertinent specialists to available out on demand. 
• Establishment of useful setups that promote the association 
establishment, which makes available help to psoriatic patients and 
families of them. 
• Organization of health-education, counseling and self-care programmes 
for patients with psoriasis. 
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RELAPSE:  
           Eventhough with different modes of treatment, psoriasis is completely 
cured; there are more chances to have relapse. With 142 patients a follow up 
study of seven years duration was done. It shows that when compare with the 
home treated patients, there is a longer remission for the persons who got 
treatment in hospital whether outpatient or inpatient. Guttate lesions had the 
better prognosis86,57
EXPERIMENTAL APPROACHES:
. 
A fusion protein and diphtheria toxin as a intravenous therapy, anti CD-
25 antibody, topical application of human recombinant IL-10 and oral 
macrolatums are some of the experimental and newer approaches .  
57 
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MATERIALS AND METHODS 
STUDY DESIGN             : CASE CONTROL STUDY 
PLACE OF STUDY       :  Department of Biochemistry and Dermatology, 
                                             Govt. Kilpauk medical college, 
                                             Chennai-10 
DURATION OF STUDY : 6 months (MARCH 2016 – AUGUST 2016) 
SAMPLE SIZE      : 90 
SAMPLE SELECTION:  
     CA11SES           :  45 newly diagnosed cases of psoriasis 
    CONTROLS    : 45 Nonpsoriatic healthy individuals with no 
Family history of psoriasis. 
STUDY POPULATION: 
INCLUSION CRITERIA:  
• Newly diagnosed psoriatic patients in the age group of 21- 60 years. 
          The diagnosis of psoriasis was confirmed in all cases by dermatologist 
based on established clinical criteria. 
EXCLUSION CRITERIA:  
          1)  Psoriatic Patients on treatment. 
          2)  Other type of skin diseases like atopic dermatitis. 
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         3)  Other inflammatory diseases like DM, HT, CAD, and BONE 
DISEASES. 
        4)  Immunosuppression, Malignancies, Autoimmune/genetic/ 
metabolic/rheumatic diseases, and bacterial, viral, or fungal 
infection up to 4 weeks. 
SAMPLE COLLECTION: 
               3ml of venous blood was drawn in a plain serum vacutainer tube 
under sterile conditions after fulfilling the selection criteria, from the 
anticubital vein with explicit informed consent. Keep the samples in a serum 
separator tube for 2 hours at room temperature to clot. Serum was separated by 
centrifugation at approximately 2000-3000rpm for 15-20min and aliquoted, 
into an eppendorf, and immediately frozen at -20⁰C and keeps it in storage until 
processed. 
               2ml of venous blood was drawn in EDTA tube for TC, DC. 
ESTIMATION OF C-REACTIVE PROTEIN: 
METHOD: Quantitative Turbidimetric Method. 
Kit used: CRP-Turbilatex 
Principle: 
           Latex particles coated with specific human anti-CRP are agglutinated 
when mixed with samples containing CRP. An absorbance change occurs due 
to agglutination which is, dependent upon the CRP contents of the patient 
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sample that can be quantified by comparison with a calibrator of known CRP 
concentration, in spectrophotometry at 540nm wavelength. 
Reagent Composition:               
Diluent  (R1) Tris buffer 20 mmol/L,  pH 8.2. Preservative. 
Latex (R2) Latex particles coated with goat IgG anti-human CRP, pH 
7.3. Preservative. 
Calibrator  (R3) Liquid Calibrator. Human Serum. C-Reactive Protein 
concentration is stated on the vial label. 
 
Reagent Preparation and Stability: 
CRP Calibrator: 
        Reconstitute with1.0 ml of distilled water. Mix gently and incubate 10 
minutes at room temperature before use. Once reconstituted is stable for 1 
month at 2-8˚ C or -20˚ C. 
Test procedure: 
1. Bring the reagent and the photometer (cuvette holder) to 37C. 
2. Assay conditions: 
- Wavelength …………540 nm 
- Temperature………….37˚C 
- Cuvette light path …… 1 cm 
3.  Adjust the instrument to zero with distilled water. 
4. Pipette into cuvette. 
Diluent R1 800 Μl 
Latex R2 200 Μl 
Calibrator or sample 5.0 μL 
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               Mix and read the absorbance immediately (A1) and after 2 minutes 
(A2
Calculations: 
) of the sample addition. 
    (A2-A1) sample          *  calibrator concentration = IU/ml CRP 
(A2-A1) calibrator 
 
Reference value: Upto 6 mg/L 
ESTIMATION OF INTERLEUKIN-23: 
Method: Enzyme Linked Immuno Sorbent Assay 
Kit used: sincere. Catalogue no: E13651016 (type II), 96T 
Principle: 
              The kit assay IL-23 level in serum, use purified human IL-23 antibody 
to coat microtiter plate wells, make solid-phase antibody, then add samples to 
wells, combined human IL-23 antibody which with HRP labeled, become 
antibody-antigen-enzyme-antibody complex, after washing completely, add 
TMB substrate solution, TMB substrate become blue color, at HRP enzyme-
catalyzed, reaction is terminated by the addition of a sulphuric acid solution 
and the color change(yellow) is measured spectrophotometrically at a 
wavelength of 450 nm. The concentrations of human IL-23 in the samples were 
determined by comparing the O.D of the samples to the standard curve.  
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Assay Procedure: 
1) Preparation of the Standard:  
- Set 10 Standard wells on the ELISA plates coated 
label①②③④⑤⑥⑦⑧⑨⑩.  
- Add Standard 100µl to ①②, then add standard diluent 50µl to 
①②, mix. 
- Take out 100µl from①②, and then add it to ③④ separately, then 
add Standard diluent 50µl to ③④, mix. 
-  Then take out 50µl from③④, and discard. 
-  Then take out 50µl from③④ and add to⑤⑥, then add       
Standard diluent 50µl to the ⑤ ⑥, mix. 
- take out 50µl from⑤⑥ and add to⑦⑧, then add Standard diluent 
50µl to the⑦⑧, mix. 
- take out 50µl from the ⑦⑧ and add to ⑨⑩, add Standard diluent 
50µl to⑨⑩, mix. 
-  take out 50µl from⑨⑩ discard. 
2) Set wells separately:  
Set Blank well and Testing sample well. (Do not add sample and HRP- 
conjugate reagent into the blank comparison wells, other each step operation is 
same) 
3)   Add Sample:  
Add Sample Diluent 40µl to testing sample well, and then add testing 
Sample 10µl (Sample final dilution is 5-fold). Then add Sample to the bottom 
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of Pre-coated well, do not touch the well wall as far as possible, and mix 
gently. 
4) Incubate:  
Incubate for 30 minute at 37˚ C after closing the plate with Closure plate 
membrane. 
5) Prepare the Washing Buffer:  
30-fold Wash Solution, diluted 30-fold with Distilled Water until 600ml 
and preserve. 
6) Washing:  
Uncover Closure plate membrane, discard liquid, dry by swing. Add 
Washing Buffer to each well, keep still for 30s then drain. Repeat this for 5 
times, dry by pat. 
7) Add enzyme: 
Except the Blank well, add HRP-Conjugate Reagent 50µl to each well.  
8) Incubate: Operation with 4). 
9) Washing: Operation with 6). 
10) Color:  
Add TMB Chromogen Solution A 50ul and then add TMB Chromogen 
Solution B 50ul to each well, evades the light preservation for 15 min at 37˚C. 
11) Stop the Reaction:  
Add Stop Solution 50µl to each well, to stop the reaction (the blue color 
change to yellow color immediately). 
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12) Assay:  
Set the OD of Blank well as zero, read absorbance at 450nm after 
adding Stop Solution within 15min. 
 The judgment of result must take the OD of Microplate reader as a 
standard, 
When use the dual-wavelength to assay, reference wavelength is 630nm. 
8. CALCULATE: 
Take the standard density as a horizontal and the OD value on the 
vertical, obtain the Standard Curve, then find out the corresponding density 
according to the sample OD value, and multiplied by the dilution multiple or 
Calculate the straight line regression equation of the standard curve with the 
standard density and the OD value,with the sample OD value in the equation, 
calculate the sample density, multiplied by the dilution factor, the result is the 
sample actual density. 
 
Note: This standard curve is provided for demonstration only. A standard curve 
should be generated for each set of samples assayed. 
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9. ASSAY PROCEDURE SUMMARY: 
 
                              
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. Performance characteristics: 
            This assay is designed to eliminate the interference by binding proteins, 
soluble receptors and other factors present in biological samples. No significant 
interference or cross reactivity between IL-23 and other cytokines. 
Detection range: 7.6pg/ml – 500mg/ml 
PREPARE REAGENTS, SAMPLES AND STANDARDS 
ADD SAMPLE ANS STANDARD, INCUBATE FOR 30 MINS AT 37 ˚C 
WASH 5 TIMES, ADD HRP-CONJUGATE REAGENT, INCUBATE FOR 30 MIN AT 37˚C 
WASH 5 TIMES, ADD CHROMOGEN SOLUTION A AND B, INCUBATE FOR 15 MINS AT 37 ˚C 
ADD STOP SOLUTION 
READ ABSORBANCE AT 450NMWITHIN 15 MIN 
CALCULATE 
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ESTIMATION OF GLUCOSE: 
Method: glucose oxidase- peroxidase method. (GOD/POD) (END POINT 
METHOD) 
Kit used: Erba. 
Principle: 
          In serum glucose is oxidized to yield gluconic acid and hydrogen 
peroxide in the presence of glucose oxidase. The enzyme peroxidase catalyzes 
the oxidative coupling of 4-aminoantipyrine with phenol to yield a colored 
quinoneimine complex. The intensity of pink colored quinoneimine dye is 
proportionate to glucose concentration and was measured at 505nm. 
   Glucose + O2  +H2O            GLOCOSE OXXIDASE             Gluconic Acid + H2O
 
2 
  H2O2 + Phenol+ 4AAP                   PEROXIDASE                 Quinoneimine dye+ H2
Reagent composition: 
O 
Enzyme reagents and standard: 
Ingredients Concentrations 
Glucose oxidase ≥ 20,000 U/L 
Peroxidase ≥ 2,000 U/L 
Phenol 10 mmol/L 
Phosphate buffer 200 mmol/L 
Glucose standard 100 mg/dl 
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Assay procedure: (Semi automated analyzer) 
       Blank Standard Test 
Sample --- --- 10μl 
Standard --- 10μl --- 
Enzyme reagent 1.0ml 1.0ml 1.0ml 
 
                Mix well after each addition and incubate at 37˚C for5 minutes. And 
read the absorbance against 505nm. 
Reference range: 
Fasting:           60-100 mg/dl 
Post prandial: 90-130 mg/dl 
ESTIMATION OF BLOOD UREA 
Method: UV - GLDH 
KIT:  Accucare 
Principle:  
             The test is performed as a kinetic assay in which the initial rate of the 
reaction is linear for a limited period of time. Urea is hydrolysed by urease to 
NH3 and CO2. The NH3
GLDH 
 produced combines with alpha-oxoglutarate and 
NADH in the occurrence of glutamate dehydrogenase to produce glutamate and 
NAD. 
Urea  +    H2
NH
O                                      2NH4 + CO2                                              
4
++ NADH + H+ + 2- oxoglutarate                            Glutamate + NAD
The initial rate of decrease in absorbance is directly proportional to the 
urea concentration in the sample. Absorbance is measured at 340nm. 
+ 
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Reagent composition: 
Reagent I: buffer reagent 
Reagent II: enzyme reagent 
Urea standard: 50 mg/dl 
           Mix 4 parts (4 ml) of buffer reagent with one part (1 ml) of enzyme 
reagent and mix gently
Assay Procedure :(Semi auto analyser) 
. 
                   
     Mixed well and absorbance measured immediately at 340 nm. 
Reference Range: 
Serum/ plasma Urea   →   15- 40 mg/dl 
ESTIMATION OF SERUM CREATININE 
METHOD   : Jaffe's Method   , Initial rate metho 
Kit used  :  ERBA 
Principle :    
Creatinine in alkaline solution reacts with picrate to form a orange-
yellow compound. The color is proportional to the concentration of creatinine 
in the sample when measured at 505nm. 
 Blank Standard Test 
Sample --- --- 10μl 
Standard --- 10μl --- 
Enzyme reagent 1.0ml 1.0ml 1.0ml 
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Reagent composition: 
 Reagent I :  Picric acid reagent. 
Picric acid –      25.8 mmol/L 
  Reagent   II:  Sodium hydroxide reagent. 
Sodium hydroxide –   95 mmol/L 
Creatinine standard:    2 mg/dl 
      Reagents were allowed to attain room temperature. Equal volumes of 
reagent 1 and reagent 2 were mixed, waited for 15 minutes before use. 
Procedure: 
 
             To 1 ml of the reconstituted reagent 100μl of the plasma was added and 
absorbance (A1) taken at 20 seconds after mixing was noted & final 
absorbance (A2) at 80 seconds were measured. 
Calculation: 
A = A2 - A1 
Creatinine (mg/dl) 
                                                      A   of standard 
= Absorbance  of Test X concentration of standard ( mg/dl) 
 Reference Range: 
Males  :     0.7 - 1.4 mg/dl 
Females :     0.6 - 1.2mg/dl 
 Blank Standard Test 
Sample --- --- 100μl 
Standard --- 100μl --- 
Enzyme reagent 1.0ml 1.0ml 1.0ml 
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TOTAL COUNT AND DIFFERENTIAL COUNT: 
Method: Electrical impedance. 
Instrument : Horiba Pentra 
Model: ES60 
 Required sample:Micro-sampling from whole boold (CBC : 30 µL - DIFF: 
53 µL)  
Principle: 
           Whole blood is passed between two electrodes through an aperture so 
narrow that only one cell can pass through at a time. The impedance changes as 
a cell passes through. The change in impedance is proportional to cell volume, 
resulting in a cell count and measure of volume. 
Reference range: 
Total count 4000- 10000 cells/cumm 
Polymorphs 40- 75 % 
Eosinophils 1-2 % 
Lymphocytes 20- 45 % 
Monocytes 2- 10% 
Basophils  0-1% 
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RESULTS 
Table 1: Ratio of male/female among controls and cases 
  
  
  
Group Total 
Control Cases  
Sex Male Count 9 17 26 
  Female Count 36 28 64 
Total Count 45 45 90 
 
              There were no signiﬁcant di fferences in male/female ratio between the 
patients and controls with p value 0.063. (p > 0.05) 
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Table 2: Age match between cases and controls in study population 
 
 
   
Group 
Total Control Cases 
Age in 
years 
20-30 Count 12 9 21 
31-40 Count 16 8 24 
41-50 Count 12 16 28 
51-60 Count 5 12 17 
Total Count 45 45 90 
 
               The age match between the cases and controls is insignificant. Here 
the p value is 0.088. That is > 0.05. 
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BLOOD, UREA AND CREATININE: 
Table 3: Shows glucose, urea and creatinine values in between cases and 
controls. 
Variables Group N Mean SD p Value 
Sugar  Control 45 137.40 66.22 0.563 
Cases  45 129.12 68.84 
UREA Control 45 18.84 4.42 0.797 
Cases  45 19.15 6.79 
Creatinine  Control 45 0.87 0.19 0.214 
Cases  45 0.82 0.15 
 
                 The table shows, the random blood sugar, creatinine and urea levels 
were within the normal range among the cases and controls. There is no 
significant difference between the controls and patients. (P> 0.05) 
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TOTAL COUNT: 
Table 4: Shows the total count between controls and cases. 
Variables Group N Mean SD p Value 
Total count Control 45 7615.56 1860.34 0.537 
Cases  45 7386.67 1631.59 
  
    The total count count between the patient and controls were not significant, 
with p value > 0.05 for al 
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DIFFERENTIAL COUNT: 
Table 5: Comparison of differential cell count between controls and cases 
Variables Group N Mean SD p  Value 
Polymorphs  Control 45 59.44 7.90 0.164 
Cases 45 57.00 8.59 
Lymphocytes   Control 45 32.82 6.66 0.265 
Cases 45 38.04 30.54 
Eosinophils  Control 45 3.98 3.81 0.203 
Cases 45 4.96 3.404 
Monocytes    Control 45 3.84 1.29 0.111 
Cases 45 4.24 1.04 
     
     The differential count between the patient and controls were not significant, 
with p value > 0.05 for all. And the DC is within normal range in both controls 
and cases. 
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POLYMORPHS: 
Table 6: Comparison of polymorphs among controls and cases 
 
            The comparison between controls and cases in polymorphs shows the p 
value is >0.05 with non significant correlation. 
 
 
  
Controls,
59.44
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57
POLYMORPHS
Variables Group N Mean SD p  value 
Polymorphs Control 45 59.44 7.90 0.164 
Cases 45 57.00 8.59 
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LYMPHOCYTES: 
Table 7: Comparison of lymphocytes between controls and cases 
Variables Group N Mean SD p  value 
Lymphocytes   Control 45 32.82 6.66 0.265 
Cases  45 38.04 30.54 
 
          The lymphocytes count among the study population shows the p value is 
> 0.05. It is insignificant. 
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EOSINOPHILS : 
Table 8: Mean comparison of eosinophils in controls and case. 
Variables Group N Mean SD p  value 
Eosinophils  Control 45 3.98 3.81 0.203 
Cases  45 4.96 3.404 
 
                  The P value is >0.05 for the eosinophils among controls and cases 
shows it is not significant. 
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MONOCYTES : 
Table 9: Mean comparison of monocytes among controls and case. 
Variables Group N Mean SD p  value 
Monocytes    Control 45 3.84 1.29 0.111 
Cases  45 4.24 1.04 
 
             The P value is not significant for monocytes in the study population, 
because the P value is > 0.05. 
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CRP: 
      Mean CRP was not significantly elevated in psoriatic patients when 
compared with controls (7.73 vs 8.04) .and statistically also not significant with 
P value 0.742 
Table 10: Mean CRP among both cases and controls 
Variables Group N Mean SD p  value 
CRP Control 45 7.73 4.27 0.742 
Cases  45 8.04 4.64 
 
   
 
 
 
 
  
controls
7.73
cases
8.04
CRP
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IL-23: 
 Table 11:  Comparison between controls and cases. 
Variables Group N Mean SD p value 
IL-23 Control 41 61.47 18.10 0.883 
Cases  45 62.26 29.74 
 
              The mean value of controls and cases does not show any signiﬁcant 
difference in the IL-23 titers. The P value is 0.898 which is > 0.05 clearly 
shows their significant relationship among the two groups. 
 
     
  
controls, 61.47cases, 62.26
IL-23
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DISCUSSION 
         The aim of my study is to estimate and assess whether IL-23 is a key 
tissue specific factor in pathogenesis of psoriasis and/or its functional capacity 
to act as a stimulating factor for the disease.   
         For the past 15 years from its discovery in 2000, IL-23 has promptly 
established as a key contributor and a probable therapeutic object in psoriasis 
than just a pro-inflammatory cytokine.5
         Recently why IL-23 gets this much importance because, it is released in 
the early onset of disease and its level in serum is inversely related to disease 
duration as per Amina Hamed Alobaidi et al study
  
1
  It is suggested by 
. 
Fotiadou C et al study in which, there is the possible 
crucial role of IL-23 and IL-17A in the early stages of the disease and activity 
of psoriasis 15
           Based on Sara Brenner study, therapies involved against the target IL-23 
is showing early success in the treatment of plaque type psoriasis vulgaris
. 
32
           As per Paola Di Meglio et al study, IL-23 was revealed has a major role 
in autoimmunity. In the past 3 years major advances in genetics, 
immunopathology and clinical findings of psoriasis, we can understand the 
fundamental role of the IL-23/Th17 axis 
.  
5
           Gretta L. Stritesky et al study supports the above statement that is; IL-23 
sustains the population of IL-17 secreting T cells, noted as Th-17 cell 
. 
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expansion or survival. Results of this study imply that IL-23 is a maintenance 
factor for the Th17 phenotype27
As per 
. 
Anna Michalak-Stoma study, even though both IL-12 and IL-23 
are present in psoriasis, IL-23, rather than IL-12, is vital during the 
pathogenesis of psoriasis. IL-23 is overexpressed in psoriatic skin, p35can be 
identified by, increased p19 and p40 mRNA levels but not always. IL-23 is 
overproduced by dermal keratinocytes, dentritic cells and in lesional psoriatic 
skin30
           Based on above mentioned studies, I came to a thought that, the IL-23 
has released from lesional keratinocyte and dentritic cells and maintain the 
population of TH-17 cells, which has a major role in pathogenesis of psoriasis.  
. 
In my study, I selected a total number of 45 patients (17 males, 28 
females) and 45 age and sex-matched controls (9 males and 36 females) in 
population who attended the dermatology clinic first time with the features of 
psoriasis and normal persons from outpatient side in Government Kilpauk 
Medical College Hospital. 
           There were no signiﬁcant differences in age among the controls and 
cases. The p value of sex match is 0.063, it is >0.05.  The P value of 
Male/female ratio between the controls and patients is 0.088 and it is 
insignificant (P>0.05).  
The selection of patients with psoriasis for my study was who are not 
undergone any previous local or systemic treatment. The patients were 
diagnosed clinically and selected for study as per dermatologist opinion. The 
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control group was included the healthy, nonpsoriatic volunteers with no family 
history of psoriasis. 
           Both patients and controls had a history, or clinically any findings or 
routine laboratory ﬁndings consist with, abnormal renal or function, or parasitic 
and any other infection.  
 The routine serum glucose, urea and creatinine estimation was done. 
The mean serum levels of blood sugar for controls was 137.40 mg/ml, while in 
psoriatic patients, it was 129.12 mg/ml. The difference was statistically not 
significant with p value 0.563(p>0. 05).  The mean serum level of serum urea 
for control was 18.84 mg/dl. And for the cases it is 19.15 mg/dl with the 
difference between the two are statistically not significant with p value 
0.797.The mean serum level of creatinine for controls was 0.87mg/dl and the 
cases 0.82 mg/dl with P value 0.214 (P >0.05) which is not significant 
statistically. So the serum sugar, urea and creatinine values are within the 
normal limits for cases and controls and statistically not significant implies that 
cases are not having any diseases which altered the above mentioned 
parameters. 
The total and differential count levels were in normal range in patient 
and controls. The total count mean is slightly higher in cases when compare 
with controls. But both the groups, the counts are within the normal limits the p 
value is > 0.05, shows it is not a significant one. In differential count, the 
polymorphs mean value is slightly lower in cases than controls and the 
lymphocytes, monocytes and eosinophils values are slightly higher in cases. 
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But for all different cell types the p value is insignificant. So that’s why in my 
study shows the lymphocytes values are slightly higher and neutrophils are 
having little bit low mean values. As per Peter J Aronson MD study, 
Neutrophils emerge very early in new psoriasis lesions. Neutrophils influences 
macrophage, Th1, Th2, and Th17 lymphocytes and their cell products 
including TGF-beta, IL-17, IL-22, and IL-23.The neutrophils count is low 
when compared to controls, otherwise within the normal limits. 
              As per E.J.Mundell et al study in 2011 in a survey in the US patients 
not receiving any treatment was almost 50% in the with mild psoriasis, 25% in 
the moderate psoriasis, and 10 percent of severe psoriasis107
              The CRP level, comparison between both controls and cases, the p 
value is 0.742, which is not significant. The mean value of CRP level in control 
is 7.73 and for cases it is 8.04 and the p value is statistically not significant. 
Both controls and cases are having CRP level above the reference range that is 
above ≥ 6 mg/L. This has some reasons as per 
. Eventhough my 
aim is study in early cases of psoriasis, but the selected cases have 
comparatively high values of lymphocytes than neutrophils is may be the 
reason as per E.J.Mundell study. 
Aydin Nazmi et al article, low 
socioeconomic status is a risk factor for elevated CRP levels, even when 
several potential mediators of this association are controlled for. High levels of 
stress built up throughout the life, which is often mostly seen in the poor and 
disadvantaged, may adversely impact health outcomes and also have 
moderately high values of CRP. The overwhelming most of the articles in 32 
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studies reported, there is inverse associations between CRP levels and 
socioeconomic status and significant differences among racial/ethnic groups, 
even after controlling for possible confounding and mediating variables.29 
               The mean value of IL-23 level in controls it is 61.47 and for cases 
62.26. In the mean value of controls and cases, there is only a little elevation in 
cases, but does not show any signiﬁcance in p values. The p value is 0.898, 
which is > 0.05 clearly shows the non significant relationship among the two 
groups. These results of my study is may be due to the sample collection from 
government hospital, mostly they are belongs to low socioeconomic group. So 
there is an alteration in inflammatory markers range in controls also as per 
Annemarie Koster et al, their study analyzed the relationship between 
socioeconomic state and several markers of inﬂammation from a large sample 
of community-dwelling adults. The result is low socioeconomic status (SES) 
has been related to higher levels of inﬂammatory markers This is moreover, as 
inflammation is essence of a biological response of the immune system and it is 
associated with increased morbidity and mortality across the age span, 
including in old age.
 In 
my study population, the persons are attending the government hospital 
invariably they have been belongs to low socioeconomic groups. 
                As per 
34 
Michael Paalani et al study, Inflammatory based risk for 
health problems may vary according to ethnicity and other demographic 
factors. Exercise, diet and body mass like factors also show influence in the 
levels of inflammatory markers.37.  
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                  As per Hideki Nakajima et al study no detectable serum levels of 
IL-23 was found in both the groups. There are possibilities that these cytokines 
may involve in the very primitive phase of psoriasis development or be present 
in the lesional skin only.
 As per Amina Hamed Alobaidi Serum levels of IL-23 highly 
significantly negatively correlated with disease duration
31  
1
 In my study there is a nonsignificance between both controls and cases 
because of both the groups are belongs to low socioeconomic status as per 
Annemarie Koster et al or may be many patients are going without treatment 
due to unawareness of the disease as per E.J.Mundell et al 
.     
34,107
              Further attempt should be mandatory in order to understand the 
inflammatory marker IL-23 in our community level and to execute 
observational studies in larger populations.  
. 
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CONCLUSION 
• Psoriasis is a common chronic inflammatory dermatological disease present 
worldwide and causes significant morbidity. Its etiology is unknown, 
however it is generally thought that a complex autoimmune inflammatory 
disease with a genetic basis. 
• Several studies put forward the fact, that psoriasis is by the Th17 cell–
mediated disease which was driven by IL-23. 
• There is increase in IL-23 values in cases when compare with controls as 
per many other studied.  
• But in this study there is an insignificant relationship between cases and 
controls in IL-23 values. 
• May be due to the study population is selected from low socioeconomic 
state people, have been relatively associated with elevated levels of 
inflammatory markers due to their lifestyle. 
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LIMITATIONS OF THE STUDY 
This study has following limitations: 
• The sample size is small. 
• The fact that the hidden history of any exclusion factors may 
interfere in this study, may be due to poverty with illiteracy. 
• Unawareness of psoriasis and no treatment for longer time or 
may be latent psoriasis.  
• However, more analysis is required to demonstrate this theory. 
Currently as far as my opinion, there is no reliable data 
concerning the prevalence of psoriasis in the general population 
of India. 
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Fig 1: World map showing the DALYs for psoriasis per 100 000, rates for 
all ages and both Sexes. Source: Adapted from IHME GBD 2010 (1).  
  
 Fig2: Early case of Psoriasis attended the Dermatology OP in KMC 
 
 
 
 
 
 
 
  
 
 
 
Fig 3: Microscopic structure of psoriasis- thinned stratum granulosum; 
extensive overlying parakeratotic scale; elongated dermal  
papillae with dilated capillaries inside; 
  
  
 
 
Fig 4: IL-23 and IL-12 structure and receptors. The IL-23 cytokine is 
compiled of 2 chains, p40 and p19, both are connected covalently and IL-
12 composed of p35 and p19. p40 is shared by IL-23 and IL-12. IL-23 
receptor consists of IL-12Rβ1 and IL-23R; the IL-12 receptor made of IL-
12Rβ1 and IL-12Rβ2. 
  
  
Fig 5: the functional comparison of IL23 and IL-12. 
  
  
 
 
 
Figure 6: Schematic representation of IL-12 and IL-23, and their receptors 
and downstream signaling pathways. 
IL-12 stimulation of JAK2 and TYK2 activity leads to phosphorylation of 
STAT4 and other STAT molecules. IL-23 also activates the JAK-STAT 
pathway but acts mainly on STAT3. IL-12 induces the production of IFN-
γ, which is required for the development of TH1 immune response. IL-23 
induces IL-17A, IL-17F and/or IL-22 and stabilizes TH
  
17 cells. 
  
 
 
 
 
 
        Fig 7: The discovery of IL-23/Th-17 immune pathway 
  
  
 
 
 
 
 
Fig 8: development and differentiation of Th17 cells 
  
  
 
Fig 9 : co-morbidities and associations with psoriasis 
  
  
 
 
 
 
 
 
Fig 10 : 
  
Illustration showing the structure of C - Reactive protein 
representing the pentameric polypeptide subunits with 2 calcium binding 
sites and 1 binding site for phosphocholine. 
  
 
Fig 11: Different types of cases attended the Skin OP in KMC, Chennai 
 
  
ANNEXURE 
 
 
 
 
                             
  
 PATIENT CONSENT FORM 
STUDY TITLE: IL-23, A NOVEL MARKER IN THE DIAGNOSIS OF 
PSORIASIS. 
STUDY CENTRE: GOVT. KILPAUK MEDICAL COLLEGE 
HOSPITAL, CHENNAI-10 
PATIENT’S NAME: 
PATIENT’S AGE: 
IDENTIFICATION NUMBER: 
I confirm that I have understood the purpose and procedure of the 
above study. I have the opportunity to ask any questions and all my 
questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in this study is voluntary and 
that I am free to withdraw at any time without giving reason, without my 
legal rights being affected. 
I understand that the sponsor of clinical study, working on 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. 
However I understand that my identity would not be revealed in any 
information released to third parties unless as required under the law. I 
agree not to restrict the use of any data or results that arise from the study. 
I hereby consent to participate in this study. 
          I hereby give permission to undergo complete clinical examination 
and diagnostic tests including hematological, biochemical and 
radiological tests. 
 
                                                                       Signature/thumb impression : 
Patient’s name and address: 
  
  
PROFORMA 
NAME:                                                              OP NO: 
AGE/SEX: 
ADDRESS:                                                       OCCUPATION: 
DATE: 
PRESENT HISORY:  
 The duration of psoriasis 
 Any prior similar episodes or other skin diseases. 
PAST HISTORY:  
 History of liver/kidney disease. 
 History of any respiratory diseases like tuberculosis. 
 PERSONAL HISTORY: 
1) H/O Smoking. Alcohol intake. 
2) H/O DM, HT, CAD, BONE DISEASES. 
3) H/O inflammatory bowel disease. 
4) H/O cancer. 
5) H/O Other type of skin diseases like atopic dermatitis. 
6) H/O drug intake for past 4 weeks. 
 
 
  
FAMILY HISTORY: 
1) H/O psoriasis. 
2) H/O any autoimmune diseases. 
ON EXAMINATION: 
GENERAL EXAMINATION: 
VITALS: 
BP:                                                                              PULSE RATE: 
CVS:                                                                            RS: 
PER ABDOMEN:                                                      CNS: 
INVESTIGATIONS: 
1) Serum C-reactive protein: Quantitative Turbidimetric Test 
2) Blood urea: UV- GLDH Method. 
3) Serum Creatinine: JAFFE’S Kinetic Method. 
4) Blood glucose random: Glucose Oxidase - Peroxidase Method. 
5) Total and Differential Count: Electrical Impedance Method 
6) Serum IL-23: ELISA Technique 
 
SL.NO. SEX SUGAR UREA CREAT TC POLY LYMPHO EOSINO MONOCYTE BASOPHIL CRP IL-23
1 Female 77.85 26.46 0.566 10,300 84 12 1 3 0 3 46.23
2 Male 223.00 14.78 0.850 6,300 66 20 9 5 0 20 65.52
3 Male 67.59 14.56 0.861 5,700 48 48 2 2 0 13 153.80
4 Male 174.40 24.13 1.097 7,000 54 43 3 4 0 6 138.90
5 Male 91.66 28.12 0.753 6,800 43 50 3 4 0 5 141.30
6 Male 74.11 20.85 0.756 10,300 67 23 5 5 0 7 105.20
7 Male 222.40 16.72 0.853 6,300 60 28 8 4 0 7 67.32
8 Female 231.30 16.65 0.581 5,500 58 33 5 4 0 6 90.36
9 Female 255.10 9.60 0.714 6,600 52 25 19 4 0 8 33.76
10 Male 154.50 18.09 0.756 6,300 45 47 4 4 0 6 39.34
11 Female 100.40 17.08 0.698 5,900 57 33 4 6 0 14 45.30
12 Female 351.00 14.24 0.735 6,300 59 29 6 4 0 15 50.86
13 Male 103.70 12.15 0.929 7,000 54 37 3 4 0 5 50.51
14 Female 108.10 12.76 0.704 9,700 66 27 4 3 0 17 34.66
15 Female 97.91 16.97 0.690 7,400 62 33 3 2 0 12 68.62
16 Female 122.30 14.92 0.757 9,600 63 30 4 3 0 7 115.90
17 Female 103.40 16.11 0.787 8,700 54 38 6 2 0 1 39.46
18 Male 101.60 16.18 1.028 9,300 67 20 8 5 0 6 42.21
19 Female 98.86 26.97 0.891 8,200 40 48 4 5 0 0 39.57
20 Male 235.90 29.34 0.982 9,200 51 41 4 4 0 6 50.56
21 Female 129.70 13.63 0.772 5,600 60 34 3 3 0 8 36.15
22 Female 350.50 21.97 0.871 6,800 47 42 6 5 0 6 71.71
23 Female 89.33 19.60 0.757 8,600 62 31 2 5 0 9 57.03
24 Female 132.80 13.52 0.569 5,600 46 36 13 5 0 10 60.76
25 Female 105.00 10.50 0.743 9,600 52 42 3 3 0 4 65.53
26 Female 103.50 16.29 0.700 5,100 49 45 2 4 0 11 39.63
27 Female 60.16 15.07 0.734 5,100 50 40 4 4 0 7 53.57
28 Male 94.97 20.78 0.902 7,400 63 30 3 4 0 9 54.61
MASTER CHART
29 Male 99.22 18.27 0.947 5,500 57 35 2 6 0 4 59.80
30 Female 83.44 10.13 0.703 7,600 65 29 2 4 0 10 84.16
31 Female 107.70 33.94 1.008 8,100 61 33 2 4 0 4 75.29
32 Female 204.70 16.47 0.953 9,300 63 27 6 4 0 13 68.44
33 Female 71.46 15.87 0.992 5,900 62 28 7 3 0 4 68.88
34 Male 78.48 34.66 0.872 9,100 66 25 3 6 0 7 38.47
35 Male 79.90 17.35 1.393 6,100 58 231 6 5 0 12 35.32
36 Male 68.21 15.35 1.070 8,700 56 33 6 5 0 5 74.09
37 Male 103.70 24.62 1.010 5,300 67 25 3 5 0 6 43.93
38 Male 133.80 16.09 0.827 7,000 51 42 2 5 0 9 36.68
39 Female 120.50 18.98 0.755 9,700 53 35 5 4 0 1 55.57
40 Female 98.33 43.12 0.958 6,700 40 44 12 4 0 14 71.03
41 Female 112.16 23.24 0.698 9,800 60 33 3 4 0 4 25.85
42 Female 104.83 21.80 0.738 6,100 63 34 6 6 0 20 28.37
43 Female 84.92 17.39 0.800 9,400 62 29 4 6 0 10 57.80
44 Female 95.60 16.07 0.602 5,700 46 33 10 5 0 8 36.32
45 Female 102.85 20.65 0.782 6,200 56 31 3 5 0 3 83.61
46 Female 130.80 27.90 0.675 7,500 66 27 2 5 0 5 90.51
47 Female 148.60 18.99 0.762 7,200 64 31 2 3 0 6 67.40
48 Female 130.70 19.96 0.693 7,400 53 38 4 5 0 6 60.00
49 Female 117.40 14.85 0.677 6,000 68 26 2 4 0 6 64.26
50 Female 174.50 20.39 0.837 7,400 57 34 6 3 0 4 60.55
51 Male 154.40 24.48 1.292 6,800 57 35 4 4 0 7 56.00
52 Male 129.10 21.18 0.917 11,800 62 27 8 3 0 9 62.36
53 Male 154.20 21.32 0.853 8,800 71 25 2 5 0 3 51.80
54 Female 179.20 21.75 0.730 10,700 70 25 3 2 0 13 33.37
55 Female 133.30 16.18 0.825 6,300 56 38 3 3 0 6 58.72
56 Female 223.10 16.54 0.847 9,400 48 35 15 2 0 3 54.80
57 Female 159.00 18.05 0.900 8,600 61 35 2 5 0 5 62.10
58 Female 104.30 17.69 1.070 9,500 62 29 5 4 0 7 45.90
59 Female 99.75 20.24 0.759 6,700 66 28 2 4 0 5 54.32
60 Female 88.99 14.89 0.884 5,200 58 33 3 6 0 11 62.00
61 Female 160.90 17.69 0.800 6,700 56 36 4 4 0 10 50.60
62 Female 120.60 18.77 1.058 7,900 50 43 4 3 0 5 31.28
63 Female 121.70 31.93 0.912 6,200 51 38 6 5 0 11 75.45
64 Male 108.60 17.87 0.944 9,900 42 33 22 3 0 17 48.85
65 Female 118.80 15.93 0.680 5,100 46 48 2 4 0 6 47.90
66 Female 108.80 23.80 0.774 4,300 45 33 2 3 0 14 65.46
67 Female 97.24 13.56 0.993 10,600 66 26 3 5 0 8 54.48
68 Female 116.30 13.88 0.756 7,000 64 32 2 2 0 6 81.01
69 Female 86.55 16.50 0.688 6,400 57 36 2 5 0 9 58.50
70 Female 89.00 14.00 0.800 8,000 61 35 2 2 0 21 62.25
71 Female 86.86 19.42 0.921 8,200 64 23 11 2 0 4 30.78
72 Female 93.81 20.06 0.772 6,600 66 27 4 3 0 7 54.15
73 Female 111.70 13.34 0.978 5,200 51 43 2 4 0 6 42.67
74 Female 103.60 17.76 0.925 10,300 59 28 9 4 0 6 39.60
75 Female 192.10 25.13 0.575 9,100 76 18 2 4 0 11 63.13
76 Female 110.90 13.12 0.773 6,700 65 30 3 6 0 5 87.90
77 Female 83.67 19.02 0.953 11,300 62 31 4 3 0 10 210.03
78 Female 78.81 13.81 0.642 8,900 67 28 1 4 0 5 60.65
79 Male 130.40 18.36 0.912 9,200 63 31 2 4 0 5 202.96
80 Male 175.60 24.85 0.977 8,000 65 27 2 6 0 5 56.80
81 Female 106.80 16.90 0.812 6,200 55 39 3 3 0 5 73.55
82 Female 115.30 24.67 0.838 6,300 68 25 4 6 0 6 35.55
83 Male 354.30 25.35 1.479 6,700 60 35 3 2 0 11 94.90
84 Male 342.90 22.19 1.461 6,800 56 40 2 6 0 8 67.90
85 Female 357.50 14.35 0.760 8,500 63 32 3 2 0 9 68.27
86 Female 89.05 9.03 0.854 5,700 64 33 1 2 0 8 96.63
87 Male 90.71 17.98 1.147 6,100 40 52 3 5 0 5 69.71
88 Female 102.90 20.64 0.882 7,000 56 38 3 3 0 3 195.83
89 Female 115.40 17.98 0.780 10,400 66 30 2 6 0 22 182.50
90 Female 85.18 15.68 0.659 4,100 52 41 3 4 0 4 116.80
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